

# Curriculum Vitae

## Jane F Apperley FMedSci

### 1 PERSONAL DETAILS

#### 1.1 CURRENT POSITION

Professor of Haemato-oncology (Honorary Consultant)  
Imperial College, London

Tel 44 (0)208 383 3237 Fax 44 (0)203 313 8223 e-mail j.apperley@imperial.ac.uk

#### 1.2 QUALIFICATIONS

Bachelor of Medicine, Bachelor of Surgery (MBChB - Birmingham)	1979
Member of the Royal College of Physicians (MRCP)	1982
Doctoral thesis (MD - Birmingham)	1988
Member of the Royal College of Pathologists (MRCPATH) (Haematology)	1991
JCHMT accreditation/Certificate of Completed Specialist Training (CCST)	1991
Fellow of the Royal College of Physicians (FRCP)	1995
Fellow of the Royal College of Pathologists (FRCPath)	1999
NIHR Senior Investigator	2012
Fellow of the Academy of Medical Science	2017
NIHR Emeritus Senior Investigator	2021

#### 1.3 PRIZES AND SCHOLARSHIPS

Honours (University of Birmingham Medical School) in Anatomy, Physiology, Biochemistry, Pharmacology, Social Medicine  
Sands-Cox Scholarship 1974-1979  
Arthur Thomson Travelling Scholarship (Minneapolis 1978)  
Tony Friend Prize in Renal Medicine 1979  
Wellcome Research Training Fellowship 1987-1989  
Medal of Honour, Polish Society of Hematology 2009  
Maedal of Honour, Hungarian Society of Hematology, 2012  
NHS London Inspirational Leader 2015  
John Goldman Memorial Lectureship, ESH-iCMLf, 2020  
Pierre Stryckmans Lectureship, Belgian Society of Hematology, 2021

#### 1.4 MEMBERSHIP OF SOCIETIES

American Society of Hematology (ASH)  
British Society of Blood and Marrow Transplant (BSBMT)  
British Society of Haematology (BSH)  
European Haematology Association (EHA)  
European Group for Blood & Marrow Transplant (EBMT)

#### 1.5 PREVIOUS POSITIONS

Aug 1979	-	Feb 1980	House Physician, Warwick Hospital, Warwick.
Feb 1980	-	Aug 1980	House Surgeon, General Hospital, Birmingham.
Aug 1980	-	Feb 1981	SHO (Haem), Northern General Hospital, Sheffield.
Feb 1981	-	Sept 1982	SHO in Medicine, Warwick Hospital, Warwick.

Sep 1982	-	Feb 1984	Registrar (Haematology), West Midlands.
Mar 1984	-	Apr 1985	BMT Co-ordinator, Royal Postgraduate Medical School, London
Apr 1985	-	Jun 1987	Clinical Research Fellow (Honorary Senior Registrar), MRC Leukaemia Unit, RPMS, London
Jul 1987	-	Sep 1989	Wellcome Research Training Fellowship Harvard University, Boston, USA.
Nov 1989	-	Dec 1991	Kay Kendall Lecturer in BMT (Honorary Senior Registrar) University of Cambridge
Jan 1992	-	Mar 1993	Senior Clinical Research Associate (Honorary Consultant) University of Cambridge
Mar 1993	-	June 2000	Senior Lecturer (Honorary Consultant) RPMS, London, (later Imperial College of Science and Medicine, ICSM)
June 2000	-	Sept 2002	Reader (Honorary Consultant) Imperial College of Science, Medicine and Technology (ICMST)
Sept 2002	-	April 2004	Professor of Haemato-oncology (Honorary Consultant) Imperial College of Science, Medicine and Technology (ICMST)]
Sept 2003	-	July 2021	Clinical Director; Haematology, Imperial College Healthcare NHS Trust
April 2004	-	April 2021	Chair of Centre for Haematology, Imperial College, London

## RESEARCH

### 2.1 RESEARCH INTERESTS

- ◆ Chronic myeloid leukaemia
- ◆ Stem cell transplantation
- ◆ Adoptive immunotherapy
- ◆ Gene therapy and its clinical translation

### 2.2 DOCTORAL THESIS

In vitro and in vivo studies of cytomegalovirus in haemopoietic stem cell transplantation (1988)

### 2.3 EDITORIAL BOARDS

Transplantation 1994-1995

Experimental Hematology 1996-1998

Bone Marrow Transplantation 1992 to date

Blood 2005-2010

Blood Reviews 2007 to date

### 2.4 RESEARCH GRANTS (1994 to date)

**1994-1997:** Leukaemia Research Fund. The mechanism of bone destruction in multiple myeloma. JF Apperley & RGG Russell. £78,941.

**1995-1998:** Kay Kendall Leukaemia Fund. Retroviral mediated gene transfer (RMGT) in chronic myeloid leukaemia and myeloma: pre-clinical studies. JF Apperley, J Vaz de Melo, DM Samson, JM Goldman. £482,000.

**1996-1998:** Leukaemia Research Fund. Quantitative molecular detection of clonal myeloma cells: clinical and biological applications. DM Samson & JF Apperley. £ 74,436.

**1997-2000:** Leukaemia Research Fund. The mechanism of bone destruction in multiple myeloma. JF Apperley & DM Samson. £197,586.

**1997:** Richard Driehaus Foundation. Molecular diagnosis of AL amyloidosis. JF Apperley. \$10,000

**1998:** European Group for Blood and Marrow Transplantation (EBMT): Minimal residual disease in multiple myeloma. JF Apperley & DM Samson. £15,000.

**1997-2000:** EU Biomed 2 Shared Cost Project PL962074. Evaluation of somatic gene therapy approaches in the management of leukaemia: in vitro and in vivo studies. JF Apperley, C Bonini, HJ Kolb, A Hagenbeek, P Tiberghin, M Lawler. £125,400.

**1998- 2001:** EU Biomed 2 Demonstration Project PL62385. Immunotherapy of leukaemia using suicide gene transduced donor lymphocytes in the context of allogeneic bone marrow transplantation. JF Apperley, HJ Kolb, A Hagenbeek, P Tiberghin, M Lawler, C Bonini. £142,000.

**1998-2000:** EU Biotechnology Demonstration Project PL970208. Gene marking in autologous stem cell transplantation. JF Apperley, F Frassoni, S Devereux, H Lokhorst, B Bjorkstrand, E Smith. £66,000.

**1999-2002:** Leukaemia Research Fund. Real time quantitative PCR to monitor patient response to treatment and to assist in the development of novel therapeutic strategies. J Kaeda, DM Samson, JF Apperley, H Stauss, N Cross. £46,616.

**1999:** MRC Co-operative Group Grant status. H Stauss, R Lechler, E Simpson, F Dazzi, C Craddock, JF Apperley, JM Goldman.

**1999-2002:** Leukaemia Research Fund. The role of the osteoprotegerin ligand system in the pathophysiology of myeloma bone disease. JF Apperley, PI Croucher. £136,043

**1999-2003:** Kay Kendall Leukaemia Fund. Retroviral mediated gene transfer for the management of chronic myeloid leukaemia. JF Apperley, J Vaz de Melo, DM Samson, JM Goldman. £412,333.

**2001-2002:** Hammersmith Hospital Trust Research Committee. Development of a test to predict resistance to STI571, a new drug for the treatment of chronic myeloid leukaemia. JV Melo, JF Apperley. £24,944.

**2002:** Hammersmith Hospital Trust Research Committee. Respiratory morbidity after allogeneic stem cell transplantation: clinical and scientific usefulness of induced sputum examination. JF Apperley, P Ind, £10,000

**2002-2005:** EU Biomed Framework V. Immunotherapy of leukaemia using suicide gene transduced donor lymphocytes in the context of allogeneic bone marrow transplantation. JF Apperley, C Baum, S Dilber, HG Eckert, E Goulmy, A Hagenbeek, HJ Kolb, M Lawler, S Mori, S Slavin, P Tiberghin, A Zander, C Bonini. £200,000.

**2002-2005:** Leukemia Society of America. Prime-boost vaccines for Chronic Myelogenous Leukemia. I Harmer, W Ouwehand, AV Hill, JV Melo, JF Apperley. \$375,000

**2003-2004:** EU Framework VI. EBMT JACIE accreditation programme. JF Apperley, A Urbano-Ispizua, F McDonald. £261,400

**2003-2005:** Leukaemia Research Fund. The mechanisms of HvG tolerance induced by low intensity conditioning allogeneic stem cell transplantation: impact of the development of new regimens. F Dazzi, R Lechler, H Stauss, JF Apperley, E Simpson. £119,086

**2003-2005:** Leukaemia Research Fund. Regulatory T cells control graft versus leukaemia after allogeneic stem cell transplantation. F Dazzi, R Lechler, JF Apperley. £67,323.

**2003-2006:** LRF Clinical Trials Committee. Support for BSBMT data manager. JF Apperley, D Marks. £75,000.

**2003-2008:** EU Biomed Framework VI. Network of Excellence – European Leukaemia Net. Principal investigator for Work Package 14 (Transplantation). Total grant £5.5 million.

**2004-2007:** EU Framework 6: Marie Curie Conference Series, European School of Hematology Education Series D Jasmin, E Gluckman, JF Apperley. £432, 200

**2005:** Leuka. Research into haematological diseases. JF Apperley £350,000

**2005-2008:** Amgen PhD studentship. JF Apperley £60,000

**2005-2008:** Leukaemia Research Fund. UK CML BioBank. £100,000.

**2006:** Leuka: Research into haematological diseases. JF Apperley £400,000

**2007:** Leuka: Research into haematological diseases. JF Apperley £370,000

**2007-2008:** EBMT-Amgen Clinical Fellowship. JF Apperley £30,000

**2007-2009:** EU Framework 6. Establishment of the infrastructure to support international prospective clinical trials in stem cell transplantation, JF Apperley on behalf of the EBMT £350,000

**2007-2010:** Novartis PhD studentship. JF Apperley £60,000

**2008:** EU Marie Curie Reintegration grant for Katy Rezvani, £80,000

**2008-2012:** HEFCE Senior Lecturership for Katy Rezvani £250,000

**2008-2010:** Kay Kendall Leukaemia Fund Development of immunotherapeutic strategies to overcome tolerance using PRAME as a novel leukaemia-associated antigen. K Rezvani, JF Apperley £149,670

**2008:** Leuka. Research into haematological diseases. JF Apperley £380,000

**2008:** Genzyme. Complications of mobilising chemotherapy. JF Apperley £50,000

**2008-2009:** NIH Bench to Bedside. Development of immunotherapeutic strategies to overcome tolerance in leukemia. K Rezvani, J Barrett, JF Apperley. £84,000

**2008-2010:** MRC pump-priming capacity development in translational medicine. JF Apperley, M Schneider, M Wilkins. £1,000,000

**2008-2018:** Bristol Myers Squibb. Molecular monitoring for NCRI UK Phase III randomised study of dasatinib vs imatinib in newly diagnosed CML (SPIRIT2). JF Apperley, L Foroni. £1,674,000

**2009:** Leuka. Research into haematological diseases. JF Apperley £360,000

**2010-2013:** Medical Research Council. Genome wide DNA methylation profiling in chronic myeloid leukaemia. JF Apperley. £300,000

**2010-2014:** HEFCE Senior Lecturership for Alfonso Quintas-Cardama £250,000

**2010:** Leuka. Research into haematological diseases. JF Apperley £376,000

**2010:** Leuka Centre for CML. JF Apperley, D Marin, £250,000

**2010-2013:** EU Framework 7. Academic GMP. JF Apperley in partnership with others in Europe

**2011:** Novartis. A Reid, JF Apperley. Genomic PCR for MRD in CML. £20,000

**2011-2014:** Leukaemia and Lymphoma Research. F Dazzi, JF Apperley, Developing a potency assay for clinical grade mesenchymal stromal cells. £206,796

**2012-2017:** NIHR Senior Investigator Award

**2012:** Leuka CML Alliance JF Apperley, D Marin, D Milojkovic. £152,000

**2012-2015:** Leuka and Novartis: Pilot study for the development of a UK CML registry £147,000

**2012:** Leuka core grant £296,000

**2012:** Leuka: epigenetics in CML £49,000

**2012-17:** NIHR Senior Investigator £500,000

**2013-2016:** EU Marie Curie Re-integration Award for Dr Niklas Feldhahn: JF Apperley £100,000

**2013-2018:** Leukaemia and Lymphoma Research. J Apperley, Bennett Fellowship for Dr Niklas Feldhahn, £650,000

**2013-14:** Leuka: JF Apperley, A Bazeos. Histone modification in CML £49,000

**2013-14:** BSH. JF Apperley, K Stringaris. Role of NK cells in AML, £7,000

**2013-14:** Leuka core grant: JF Apperley. Research into haematological malignancies, £201,000.

**2013-18:** NIHR-BRC Haematology theme leader JF Apperley £650,000

**2013-14:** Leuka: JF Apperley, A Bazeos, Epigenetics in CML, £46,000

**2014-15:** BSH. JF Apperley, G Nteliopoulos. Histone modification in CML, £7,000

**2014-17:** NIHR-BRC: JF Apperley, G Nteliopoulos. Histone Modification as a biomarker in CML, £120,000  
**2014-17:** University of Liverpool UK DESTINY Study Molecular Monitoring. JF Apperley. L Foroni. Up to £537,600  
**2014-15:** Gabrielle's Angels: JF Apperley. Improving technology for detection of minimal residual disease £20,000  
**2015-17:** Elizabeth Taylor Fund: JF Apperley. Developing molecular diagnosis in MPD by NGS £36,000  
**2016-20:** Ariad, Pfizer: JF Apperley. CML Clinical Fellowship. £259,000  
**2016-18:** MRC Clinical Research Fellow in myeloma, £150,000  
**2016-19:** ICHNT Clinical Research Fellow, £150,000  
**2017-22:** NIHR-BRC Cancer & Haematology theme co-leaders RC Coombes, JF Apperley £3,250,000  
**2017-22:** CRUK-ECMC co-applicant. Total award Haematology award £120,000  
**2017-19:** Novartis: improving patient pathways in CML/MPD £25,000  
**2018-21:** NIHR Senior Investigator £300,000  
**2018:** Hugh and Josseline Langmuir Centre for Haematology £10,000,000  
**2019-22:** UK CML Registry Incyte and Pfizer £300,000  
**2020-24:** Imperial College Junor Research Fellowship for Ozgen Deniz £300,000  
**2020-23:** Daphne Jackson Fellowship for Victoria Okolie ££120,000  
**2021-21:** Novartis Global Award: prevalence of SARS-COV-2 infection in CML, £11,000

## 2.5 CLINICAL TRIALS since 2000

1. Phase II study to determine the safety and anti-leukaemic effects of STI571 in patients with Philadelphia chromosome-positive leukaemia including acute lymphoblastic leukaemia, acute myeloid leukaemia, and accelerated phase chronic myeloid leukaemia. Start date 01.10.99. Sponsor Novartis
2. Phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukaemia who are refractory to or intolerant of interferon- $\alpha$ . Start date 01.10.99. Sponsor Novartis
3. Phase III study of STI571 versus interferon- $\alpha$  (IFN- $\alpha$ ) combined with cytarabine (Ara-C) in patients with newly diagnosed previously untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia in chronic phase (CML-CP). Start date 01.06.00. Sponsor Novartis
4. Phase I/II study of the adjuvant use of imatinib in patients undergoing reduced intensity allogeneic stem cell transplantation for chronic myeloid leukaemia. Start date 20.04.02. Sponsor Imperial College.
5. CA180013 : a phase II study of BMS-354825 in subjects with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia who have disease that is resistant to high dose imatinib mesylate (Glivec) or who are intolerant of imatinib. Start date 01.02.05. Sponsor Bristol Myers Squibb. Role National PI
6. CA180005: a phase II study of BMS-354825 in subjects with accelerated phase chronic myeloid leukemia (CML) resistant to or intolerant of imatinib mesylate. Start date 01.02.05. Sponsor Bristol Myers Squibb. Role National PI
7. CA180006 : a phase II study of BMS-354825 in subjects with blast phase chronic myeloid leukemia resistant to or intolerant of imatinib mesylate. Start date 01.02.05. Sponsor Bristol Myers Squibb. Role Co-Investigator
8. CA180015: a phase II study of BMS-354825 in subjects with lymphoid blast chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. Start date 01.02.05. Sponsor Bristol Myers Squibb. Role Co-Investigator
9. CA180017: a randomised multicentre open-label study of BMS-354825 vs. imatinib mesylate (Glivec) 800mg/d in subjects with chronic phase Philadelphia chromosome-positive CML who have disease that is resistant to imatinib at a dose at 400-600mg/d. Start date 01.02.05. Sponsor Bristol Myers Squibb. Role Co-Investigator
10. A pilot trial of homoharringtonine in combination with imatinib for patients who have achieved cytogenetic remission on imatinib. Start date 01.08.05. Sponsor Imperial College. Role Co-Investigator
11. A pilot trial of homoharringtonine in combination with imatinib for patients who have achieved complete haematological response on imatinib but a) have not achieved complete cytogenetic remission or b) having achieved complete cytogenetic remission are in stable molecular response. Start date 01.08.05. Sponsor Imperial College. Role Co-Investigator
12. Phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Glivec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematologic malignancies. Start date 15.09.05. Sponsor Novartis. Role Co-Investigator

13. CA180-034: a randomised two-by-two, multicenter, open-label phase III study of BMS-354825 administered orally at a dose of 50 mg or 70mg twice daily or 100mg or 140mg once daily in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia who are resistant or intolerant to imatinib mesylate (Glivec). Start date 21.02.06. Sponsor Bristol Myers Squibb. Role Co-Investigator
14. CA180-035: a randomized two-arm multi-center, open-label phase II study of BMS-354825 administered orally at a dose of 70 mg twice daily or 140 mg once daily in subjects with chronic myeloid leukaemia in accelerated phase, in myeloid or lymphoid blast phase or with Philadelphia chromosome positive acute lymphoblastic leukaemia who are resistant or intolerant to imatinib mesylate (Glivec). ). Start date 21.02.06. Sponsor Bristol Myers Squibb. Role Co-Investigator
15. A phase II, multicentre, open-label, single arm, extension study of maintenance treatment with subcutaneous hemisynthetic homoharringtonine (HHT) as a single agent in patients with chronic myeloid leukemia (CML) who received HHT in Stragen study HHT-CML/INTL/04.2 and have achieved a complete hematological response (CHR) or returned to chronic phase. Start date 15.05.06. Sponsor Imperial College. Role Co-investigator
16. A phase II multicentre, single-arm, open-label study of subcutaneous hemi-synthetic homoharringtonine (HHT) alone in patients with accelerated phase chronic myeloid leukemia (CML) who are refractory to, or have relapsed on imatinib mesylate Start date 15.05.06. Sponsor Imperial College. Role Investigator
17. A phase II open-label study of the subcutaneous administration of homoharringtonine (CGX-635) in the treatment of patients with chronic, myeloid leukemia (CML) with the T315I BCR-ABL gene mutation. Start date 21.02.07. Sponsor Imperial College. Role Investigator
18. An open-label, multicentre, expanded access study of oral AMN 107 in adult patients with imatinib (Glivec®/Gleevec®)- resistant or – intolerant chronic myeloid leukaemia in blast crisis, accelerated phase or chronic phase. Start date 21.02.07. Sponsor Novartis. Role National PI
19. CA180043: an open-label, randomised study of dasatinib vs. high-dose (800mg) imatinib in the treatment of subjects with chronic phase chronic myeloid leukemia who have had a suboptimal response after at least 12 months of therapy with 400 mg imatinib. Start date 01.03.07. Sponsor Bristol Myers Squibb. Role Investigator
20. SPIRIT2: A phase III, prospective randomised comparison of Imatinib (STI571, Glivec/Gleevec) 400mg daily versus Dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia. Start date 01-06-07. Sponsor Newcastle University. Role Co-PI
21. A phase II open-label study of the subcutaneous administration of homoharringtonine (CGX-635) in the treatment of patients with chronic myeloid leukaemia (CML) who have failed or are intolerant to tyrosine kinase inhibitor therapy. Start date 15.01.08. Sponsor Imperial College. Role Co-investigator.
22. ENESTnd CAMN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase. Start date 15.01.08. Sponsor Novartis. Role Investigator.
23. Phase I/II study of SKI-606 in Ph-positive leukaemias. Start date 01.03.08. Sponsor Wyeth. Role National PI.
24. Phase III open label Study of bosutinib vs imatinib in subjects with newly diagnosed chronic myeloid leukaemia. Start date 01.04.08. Sponsor Wyeth. Role National PI.
25. WIN trial WT1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Start date 01-10-09. Sponsor CRUK. Role Investigator.
26. CHOICES A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with chronic myeloid leukaemia (CML) in cytogenetic response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR). Start date 01-06-09. Sponsor University of Glasgow. Role Co-investigator.
27. PACES: A pivotal phase 2 trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL mutation. Start date 01-05-11. Sponsor Ariad. Role National PI
28. EPIC A phase III, prospective randomised comparison of Imatinib 400mg daily Ponatinib 45mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia. Start date 01-04-13. Sponsor Ariad. Role Co-investigator.
29. DESTINY A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy Start date 01-04-14. Sponsor University of Newcastle. Role Co-investigator.
30. A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome. Start date 01-12-05. Sponsor GSK. Role National PI.
31. ENESTPath A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID. Start date 01-02-15. Sponsor Novartis. Role: National PI

32. A retrospective observational research study to describe the real world use of bosutinib in the UK and Netherlands, Start date 01-11-15. Sponsor Pfizer. Role: National PI
33. A multicenter phase 3, open-label study of bosutinib versus imatinib in adult patients with newly diagnosed chronic phase chronic myelogenous leukemia Start date 01-06-14. Sponsor Pfizer. Role: Co-inverstigator
34. A randomized, open-label study of ponatinib versus nilotinib in patients with chronic myeloid leukemia in chronic phase following resistance to imatinib. Start date 01-06-16. Sponsor Ariad. Role: National PI
35. OPTIC: a randomized, open-label, phase 2 trial of ponatinib in patients with resistant chronic phase chronic myeloid leukemia to characterize the efficacy and safety of a range of doses. Start date 01-12-15. Sponsor Ariad. Role: National PI
36. A phase I/IIa dose escalation and subsequent cohort expansion study of the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of intravenously administered DTP3 in patients with relapsed or refractory multiple myeloma. Start date 01-08-16. Sponsor Imperial College. Role Chief Investigator
37. A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors. Start date 01-06-2018. Sponsor Novartis. Role Chief Investigator
38. A randomized, double-blind, placebo-controlled phase III study of INCB039110 or placebo in combination with corticosteroids for the initial systemic treatment of grade II-IV acute graft-versus-host disease. Start date 01-06-2018. Sponsor Incyte. Role National PI
39. A two-part phase 1/2 study to determine safety, tolerability, pharmacokinetics, and activity of K0706, a novel tyrosine kinase inhibitor (TKI), in healthy subjects and in subjects with chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) Start date 01-07-2018. Sponsor Sun Pharma. Role National PI
40. A Phase II study of ABL001 in combination with standard tyrosine kinase inhibitor therapy to enhance molecular responses in CML. Sponsor Novartis. Role National PI. Start date Q4 2018

### 3 TEACHING

#### 3.1 UNDERGRADUATE TEACHING

Clinical tutor	University of Birmingham	1982-1984
Clinical tutor	University of Cambridge	1990 - 1992
Lecturer	Imperial College, London	1998 - to date
BSc supervisor	Imperial College, London	2005 – to date

#### 3.2 POSTGRADUATE TEACHING

##### 3.2.1 Research students

###### MSc studentships completed

Michael Scott	The culture of peripheral blood stem cells as an aid to predicting the success of PBSC transplantation (distinction), 1992
Erica Coelho	Immunophenotypic and molecular characterisation of cell lines derived from patients with multiple myeloma, 1995.
Hoda Fattani	Expression of syndecan-1 in normal and malignant cells by immunohistochemistry, 1998.

###### MPH studentships completed

Hilda Owiti	Equity of access to stem cell transplantation in the United Kingdom, 2010
-------------	---

###### MPhil studentships completed

Natali' Rossi	Kinase domain mutations in chronic myeloid leukaemia 2014
---------------	---

###### MD studentships completed

David Marin	The use of imatinib mesylate in the management of CML, 2007
Seonaid Pye	Differential gene expression in genetically modified and non-modified CD4/CD25 regulatory T-cells, 2009

### **MD studentships ongoing**

George Nesr Development and impact of a population-based registry in CML

### **MRes studentships completed**

George Nesr Effect of ponatinib on tyrosine kinase domain mutations as detected by next-generation sequencing in patients with chronic myeloid leukaemia (Clinical Research) 2016

Georgios Nteliopoulos Mutation analysis of epigenetic modifiers in chronic myeloid leukaemia (CML) using next generation sequencing (Cancer Biology) 2016

Ruta Maniusste

### **PhD studentships completed**

Michael Scott Biology and clinical application of peripheral blood stem cells mobilised by pharmacological agents, 1993.

Amina Abusedra Characterisation of the immunoglobulin lambda light chain in lymphoproliferative disorders, 1999

Dominic Elliston The use of suicide genes in models of chronic myeloid leukaemia, 2002

Angela Miller The use of suicide genes in the treatment of chronic myeloid leukaemia, 2004

Marta Serafini The role of CD20 as a suicide gene, 2007

Dan Sears Identification of PI3K/Akt targets in chronic myeloid leukaemia 2009

Jamshid Sourori Predicting resistance to tyrosine kinase inhibitors 2010

Dr Vasiliki Papadopoulou Control of Bcl-6 expression 2010

Kate Stringaris Investigating the interactions between natural killer cells and leukaemia 2014

Alex Bazeos Genome-wide DNA methylation profiling in chronic myeloid leukaemia 2016

Mary Alikian Personalised genetic management of CML 2016

Simone Claudiani Pathogenesis of chronic myeloproliferative neoplasms

### **PhD studentships ongoing**

Charlotte Read Patient-provider communication on clinical outcomes, healthcare resource utilization, engagement, and clinical trial recruitment

### **3.2.2 Post-doctoral fellows**

Peter Croucher

Alison Bybee

Roger Gooding

Elaine Garrett

Carmen Rivas

Marina Garin

Sarah Markt

David Marin

Seonaid Pye

Georgios Nteliopoulos

Mary Alikian

Kathy Dominy

Hara Nikolakopoulou

### **3.2.3 Teaching Courses**

Imperial College Bachelor of Science (Haematology)  
Bachelor of Science (Immunology)  
Bachelor of Science (Medical Biosciences)  
Diploma in Internal Medicine  
Diploma in Clinical Pathology  
Master of Research (Cancer Biology)  
Master of Research (Clinical Research)  
Master of Science (Haematology)  
Master of Science (Immunology)  
Master of Science (Molecular Medicine)  
MB BS



Teaching for the Membership of the Royal College of Physicians  
Teaching for the Fellowship of the Royal College of Pathologists  
Annual Specialist Courses at Imperial College  
Advances in Haematology  
Advances in General Practice  
Advances in Oncology  
Advances in Immunology  
Advances in Respiratory Medicine  
Haematological Oncology for Nurses

National/International American Society of Hematology: Educational Session Chair 2018  
ASBMT-CIBMTR: Scientific Chair 2019  
British Society of Blood and Marrow Transplant: Educational sessions  
British Society of Haematology: Educational sessions  
EBMT Education Committee (Chair 1999-2006), now member  
European School of Haematology Education Committee 2003-2013  
European School of Oncology  
European Haematology Association Education Committee  
ESH-EBMT training course in stem cell transplantation 1995 - 2015  
ESH-EBMT Graft vs Leukaemia and GvHD courses  
ESH-EHA morphology course for myeloproliferative diseases  
Invited educational talks at the National Haematology and/or Transplant Societies of  
Argentina, Australia, Austria-Germany-Switzerland, Belgium, Brazil, Canada, Chile,  
Czech Republic, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary,  
India, Iran, Ireland, Italy, Japan, Malaysia, Norway, Poland, Portugal, Qatar, Romania,  
Russia, Saudi Arabia, Spain, Sweden, Thailand, Turkey, UK, USA (ASCO, ASH,  
CIBMTR, TCT)

Named lectureships Mortimer Bortin Lecture, ASBMT-CIBMTR Tandem meeting 2016  
John Goldman Lecture, ESH-iCMLf meeting, 2020  
Pierre Strickmans Lecture, Belgian Society of Hematology, 2021

## **4 ADMINISTRATION AND PROFESSIONAL ACTIVITIES**

### **4.1 UNIVERSITY AND NATIONAL HEALTH SERVICE HOSPITAL TRUST**

Chair North-West London Sector for Haematology 2020 to date  
Clinical Director for Clinical Haematology 2003 to 2021  
Theme Leader for Haematology, Biomedical Research Centre 2007-2017  
Co-director for Theme for Cancer, Biomedical Research Centre 2017-2022  
Programme Director, Stem Cell Transplantation 1994-2016  
Director Stem Cell Laboratory 2016 to date  
Clinical Programme Group 6 Board member 2005-2012  
Divisional Committee of Surgery, Cancer and Cardiovascular Medicine: member 2012 to 2021  
Imperial College Department of Immunology and Inflammation Executive Committee member 2019-2021  
Imperial College Department of Medicine Management Board: member 2015 to 2019  
Imperial College Division of Experimental Medicine, board member 2004 to 2019  
Imperial College Department of Immunology and Inflammation EDI committee member 2019-2021  
Imperial College Athena Swan Committee: member 2016 to 2019  
Member: Imperial College Research Ethics Committee 2001-2011  
Member: antibiotic policy group  
Member: cytotoxic drugs policy group  
Organiser: departmental 'Open Day' for referring physicians  
Organiser: departmental 'Open Day' for general practitioners

### **4.2 NATIONAL**

**Academy of Medical Sciences: Fellow 2017**

**BACUP:** Specialist advisor

**Blood Cancers UK (previously LLR/LLR, Bloodwise):** patient advisory board 2012 to date

**British Committee for Standards in Haematology:** Clinical Haematology Task Force 1994-1999

**British Society of Blood and Marrow Transplant:** President 2003-2005, Executive Committee member 1994-2000, Chair of Clinical Trials Committee 2000-2003, President-elect 2001.

**Cancer Research Campaign** study of targeted radiotherapy in haematological malignancies: study co-ordinator  
Clinical Reference Group for stem cell transplantation: north-west London representative

**Founder:** UK CML patient seminar 1998 to date

**Healthcare Resource Group:** Expert working group member, Chapter 5 Haematology

**International Myeloma Forum (IMF) UK:** Scientific Advisory Board member, Patient group advisor

National SACT Consent Steering Group

**NCRI Working Party on CML:** Member 2000 to date

**NCRI Working Party on Adult Leukaemia**

**NICE Guidance on Haematological Cancers:** member and chair of proposal generating event

**NICE Advisory Board** for use of tyrosine kinase inhibitors in chronic myeloid leukaemia

**NIHR: Senior Investigator:** 2012 to date

**Reviewer of grants** for Barts Cancer Charity, CRUK, Cystic Fibrosis Society, Kay Kendall Leukaemia Foundation, Leukaemia Research Fund/Bloodwise/Blood Cancers UK, MRC NIHR< Wellcome, Yorkshire Cancer Society and Welsh Office

**Royal College of Obstetricians and Gynaecologists Working Party** on the storage of ovarian and pre-pubertal testicular tissue: member

**Royal College of Obstetricians and Gynaecologists Working Party** on the management of cancer in pregnancy, member

**Royal College of Pathologists:** Regional representative for NW Thames ('94-'98)

**SACT National Steering Group:** member 2018 to date

**UK Myeloma Forum:** Founder member & member of Project Executive Committee (1998-2000)

**West London Cancer Network:** Steering committee member

### **4.3 INTERNATIONAL**

**American Society of Hematology**

Nominating Committee 2016-2020

Chair Education Session on CML 2018  
 International Members Committee 2002-2005  
**ATIP-Avenir, France** Member then Chair LS4 Scientific Panel 2016-2018  
**CIBMTR Advisory Board:** European vice-president 2009-2013, 2017-2020  
**European Group for Blood & Marrow Transplant (EBMT)**  
 President 2002-2006  
 Board member, 1994-2000, 2001 to date  
 Chairman, Chronic Leukaemia Working Party, 1994-2000, member 1994 to date  
 Late Effects Working Party member, 1993 to date  
 Infectious Diseases Working Party member, 1998 to date  
 Registry Executive Committee, 1998-2000, 2002 to date  
 Education sub-committee, 1996 to date: Chairman 1999-2006  
 Outreach sub-committee, 2001 to date  
 President: annual meeting London April 2013  
**European Hematology Association:** Scientific Organising Committee. 2001 to date  
 Scientific Working Group on CML: Chair 2020 to date  
 European Leukemia Net  
**European Investigators in CML**  
 Annual meeting organizer, Oxford 2007, Windsor 2022  
**European LeukemiaNet**  
 Chair Transplantation Working Group 2005 to date  
 Member CML Working Group 2005 to date  
 Lead author CML Consensus Recommendations for Management of CML 2021 to date  
**European Society of Gene Therapy**  
 Founder member, 1991.  
 Board member and Secretary to the Board, 1995-2000.  
**European School of Haematology**  
 Organising Committee member 1999 to date  
 Education Committee member 2001 to date  
**European Research Council** Starting Investigators Awards, panel member 2007-2011  
**European Research Council** Starting Investigators Awards, panel chair 2011-2014  
 European Research Council: Synergy Awards, reviewer 2013-2017  
**JACIE:** member executive committee 2001-2006, Vice-President, President 2006-2010, past President 2010-2012  
**INSERM:** Site visitor 2009 to date  
**Institut National du Cancer:** grant reviewer, comprehensive cancer centre awards, panel member  
**International advisory panel: University of Hannover, Germany**  
**International advisory panel: SAKK, Bern, Switzerland**  
**International advisory panel: University of Jena, Germany**  
**International Bone Marrow Transplant Registry:** Executive Committee; member, Advisory Committee; member  
**International CML Foundation;** Board member and Trustee 2014 to date  
**International Society of Experimental Haematology:** Membership Committee 1996-2000  
**International Society of Cancer Gene Therapy:** Council member  
**Promotion Committees:** Trinity University Dublin, University of Tel Aviv, University of Vienna,  
**Reviewer of grants** for the AIRC, Italy, ATIP-Avenir (France), Hungarian Medical Research Council, Inserm France, INCa France, Inser (France), Italian Leukaemia Society, Italian Research Council, La Caixa (Spain), Norwegian Medical Research Council, Qatari Government, Swedish Medical Research Council,  
**Reviewer** for the journals Blood, Bone Marrow Transplantation, British Journal of Haematology, Experimental Hematology, Frontiers in Oncology, Hematologica, Gene Therapy, Human Gene Therapy, Journal of Clinical Oncology, Lancet, Lancet Hematology, Lancet Oncology, Leukemia, Leukemia and Lymphoma, Leukemia Research, New England Journal of Medicine, Oncotarget, Therapeutic Advances in Hematology, Transplantation.  
**Transplant and Cellular Therapy Meetings 2019, Houston USA:** Scientific Chair  
**World Marrow Donor Association:** Chair of the Clinical Working Group 2000- 2002  
**World Blood and Marrow Transplant Network:** Chair of Transplant Center Working Group 2010-2018

## 5 PUBLICATIONS

### 5.1 *Original refereed international journal articles*

- 5.1.1 Boughton BJ, Franklin IM, Apperley JF, Knight D. Non-cardiotoxic anthracycline regimens in the treatment of acute myeloblastic leukaemia. *British Journal of Haematology* 1984 58: 378-80.
- 5.1.2 Braude S, Apperley JF, Krausz T, Goldman JM. Adult respiratory distress syndrome after allogeneic bone marrow transplantation: evidence for a neutrophil-independent mechanism. *Lancet* 1985 i: 1239-1242.
- 5.1.3 Goldman JM, Apperley JF, Marcus RE, Hows JM et al. Bone marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia: apparent low incidence of relapse in the first two years post-BMT. *Exper Hematol* 1985; 13: 14-15.
- 5.1.4 Goldman JM, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukaemia. *New England Journal of Medicine* 1986 314: 202-207.
- 5.1.5 Patterson J, Prentice HG, Brenner MK, Gilmore M, Janossy G, Ivory K, Skeggs D, Morgan H, Lord J, Blacklock HA, Hoffbrand AV, Apperley JF, Goldman JM, Burnett A, Gribben J, Alcorn M, Pearson C, McVickers I, Hann IM, Reid C, Wardle DG, Bacigalupo A and Robertson AG. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. *British Journal of Haematology*. 1986 63: 221-230.
- 5.1.6 Apperley JF, Rassool F, Parreira A et al. Philadelphia positive metaphases in the marrow after bone marrow transplantation for chronic myeloid leukaemia. *American Journal of Haematology* 1986 22: 199-202.
- 5.1.7 Apperley JF, Jones L, Hale G et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. *Bone Marrow Transplant*. 1986 1: 53-66.
- 5.1.8 Hows JM, Yin JL, Marsh JM, Jones L, Apperley JF, James DCO, Smithers S, Batchelor JR, Goldman JM and Gordon-Smith EC. Histocompatible unrelated volunteer donors compared with HLA non-identical family donors in marrow transplantation for aplastic anaemia and leukaemia. *Blood* 1986 68: 1322-1328.
- 5.1.9 Bull BS, Levy WA, Westengard JO, Farr M, Smith PF, Apperley JF, Bacon PA and Stuart J. Ranking Laboratory tests by consensus analysis. *Lancet* 1986 ii: 377-380.
- 5.1.10 Cohen J, Moore RH, Al-Hashimi S, Jones L, Apperley JF, Aber VR. Antibody titres to a rough-mutant strain of *Escherichia Coli* in patients undergoing allogeneic bone marrow transplantation: evidence of a protective effect against graft-versus-host disease. *Lancet* 1987 i: 8-11.
- 5.1.10 Apperley JF, Rice SJ, Bishop JA et al. Late onset haemorrhagic cystitis associated with urinary excretion of papovaviridae after bone marrow transplantation. *Transplantation* 1987 43: 108-112.
- 5.1.11 Parriera A., Smith J, Smithers SA, Hows JM, Apperley JF, Rombos Y, Goldman JM, Gordon-Smith EC and Catovsky D. Immunological reconstitution after bone marrow transplantation with Campath-1 treated bone marrow. *Clinical and Experimental Immunology* 1987 67: 142-150.
- 5.1.12 Jones L, Ball J, Apperley JF, Ginsberg L and Goldman JM. Subacute thyroiditis after bone marrow transplant (BMT) for chronic granulocytic leukaemia. *Bone Marrow Transplant*. 1987 1:411-412.
- 5.1.13 Apperley JF, Rice SJ, Hewitt P, Rombos Y, Barbera J and Goldman JM. HIV infection after bone marrow transplantation. *European Journal of Haematology*. 1987 39: 185-189.
- 5.1.14 Jones L, Thein SL, Jeffreys AJ, Apperley JF, Catovsky D and Goldman JM. Identical twin marrow transplantation for 5 patients with chronic myeloid leukaemia: role of DNA finger-printing to confirm monozygosity in 3 cases. *European Journal of Haematology*. 1987 39: 144-147.
- 5.1.15 Brito-Babapulle F, Apperley JF, Rassool F, Guo AP, Dowding C and Goldman JM. Complete remission after autografting for chronic myeloid leukaemia. *Leukemia Research* 1987 11: 1115-1117.

- 5.1.16 Gao LM, Hibbin J, Arthur C, Apperley JF, Jeffreys AJ and Goldman JM. Use of minisatellite DNA probes for recognition and characterisation of relapse after allogeneic bone marrow transplantation. *British Journal of Haematology* 1988 68:195-201.
- 5.1.17 Sutedja T, Apperley JF, Hughes JMB et al. Pulmonary function after bone marrow transplantation for chronic myeloid leukaemia. *Thorax* 1988 43: 163-169.
- 5.1.18 Arthur C, Apperley JF, Guo AP, Rassool F, Gao LM and Goldman JM. Cytogenetic events after bone marrow transplantation for chronic myeloid leukaemia in chronic phase. *Blood* 1988 71: 1179-1186.
- 5.1.19 Apperley JF, Mauro FR, Goldman JM et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. *British Journal of Haematology* 1988 69: 239-246.
- 5.1.20 Apperley JF and Goldman JM. Cytomegalovirus: cell biology, disease and methods of diagnosis. *Bone Marrow Transplant.* 1988 3: 253-264.
- 5.1.21 Apperley JF, Dowding C, Hibbin J et al. The effect of cytomegalovirus infection on haemopoiesis: in vitro evidence for selective infection of marrow stromal cells. *Experimental Hematology* 1989 17: 38-45.
- 5.1.22 James ND, Apperley JF, Kam KC et al. Total lymphoid irradiation preceding bone marrow transplantation for chronic myeloid leukaemia. *Clinical Radiology* 1989 40:195-198.
- 5.1.23 Brito-Babapulle F, Marcus R, Apperley JF et al. Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. *British Journal of Haematology* 1989 73: 76-81.
- 5.1.24 Lim B, Apperley JF, Orkin SH, Williams DA. Long-term expression of human adenosine deaminase in murine haemopoietic cells. *Proceedings of the National Academy of Sciences* 1989 86: 8892-8896.
- 5.1.25 Hughes TP, Economou K, MacKinnon S, Vlitos M, Arthur CK, Guo AP, Rassool F, Apperley JF, Hows J, Goldman JM. Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. *British Journal of Haematology* 1989 73: 462-467.
- 5.1.26 MacKinnon S, Hows JM, Goldman JM, Arthur CK, Hughes T, Apperley JF, Jones L, Batchelor JR, Brookes P, Catovsky D, Galton DAG, Bidwell J, Bradley B, Cleaver S, Hale G, Waldmann H. Bone marrow transplantation for chronic myeloid leukaemia: the use of histocompatible unrelated volunteer donors. *Experimental Hematology* 1990 18: 421-425.
- 5.1.27 Luskey BD, Lim B, Apperley JF, Orkin SH, Williams DA. Gene transfer into murine hematopoietic stem cells and bone marrow stromal cells. *The Annals of the New York Academy of Sciences.* 1990. 612: 398-406.
- 5.1.28 Apperley JF, Luskey BD, Williams DA. Retroviral-mediated gene transfer of human adenosine deaminase into murine hemopoietic cells. *Seminars in Hematology* 1991 28: 170-176.
- 5.1.29 Apperley JF, Luskey BD, Williams DA. Retroviral gene transfer of human adenosine deaminase in murine hemopoietic cells: effect of selectable marker sequences on long-term expression. *Blood.* 1991 78: 310-317.
- 5.1.30 Richards EM, Apperley JF, Marcus RE. Successful use of liposome encapsulated amphotericin to treat invasive aspergillosis following failure of conventional amphotericin. *Clinical and Laboratory Haematology.* 1992 14: 127-130.
- 5.1.31 Marks DI, Hughes TP, Szydlo R, Kelly S, Cullis JO, Schwarzer AP, MacKinnon S, Apperley JF, Barrett AJ, Hows JM, Goldman JM. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. *British Journal of Haematology.* 1992 81: 383-90.
- 5.1.32 Craddock CF, Apperley JF, Wright EG, Healy LE, Evans M, Grimsley PG, Gordon MY. Circulating stem cells in mice treated with cyclophosphamide. *Blood* 1992 80: 264-269.

- 5.1.33 Arcese W, Goldman JM, D'Arcangelo E, Schattenberg A, Nardi A, Apperley JF et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia: a retrospective analysis. *Blood* 1993 82: 3211-3219.
- 5.1.34 Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, Bandini G, Carreras E, Vernant JP, Bosi A, de Witte T, Fibbe WE, Zwaan F, Michallet M, Ruutu T, Devergie A, Irondo A, Apperley JF, Reiffers J, Speck B, Goldman JM, for the Chronic Leukaemia Working Party of the EBMT. Bone marrow transplantation for chronic myeloid leukaemia: long term results. *Bone Marrow Transplantation* 1993 12: 509-516.
- 5.1.35 Bird JM, Bloxham D, Samson D, Marcus RE, Russell NH, Kelsey SM, Newland AC, Apperley JF. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. *British Journal of Haematology* 1994 88: 110-116.
- 5.1.36 Goldring MB, Birkhead JR, Suen LF, Yamin R, Mizuno S, Glowacki J, Arbiser J, Apperley JF. Interleukin-1b modulated gene expression in immortalised human chondrocytes. *Journal of Clinical Investigation* 1994 94: 2307-2316.
- 5.1.37 Healy LE, Nirsimloo N, Scott M, Apperley JF, Gordon MY. In vitro proliferation of cells mobilised into the peripheral blood for collection and autologous transplantation. *Experimental Hematology* 1994 22: 1278-1282.
- 5.1.38 Gratwohl A, Hermans J, Apperley JF, Arcese W, Bacigalupo A, Bandini G, Boogaerts M, Bosi A, Carreras E, Devergie A, Ferrant A, Fibbe WE, Frassoni F, Gahrton G, Goldman JM, Irondo A, Jacobsen N, Kolb HJ, Link H, Michallet M, Prentice HG, Reiffers J, van Rhee F, Ruutu T, Torlantano G, Schweikhofer H, Vernant JP, de Witte T, Niederwieser D. Acute graft versus host disease: grade and outcome in patients with chronic myelogenous leukaemia. *Blood* 1995, 86: 813-818.
- 5.1.39 Scott MA, Ager S, Apperley JF, Jestice HK, Bloxham D, Boraks P, O'Connor S, Tolliday BH, Marcus RE. Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma. *Leukaemia and Lymphoma* 1995, 19: 479-484.
- 5.1.40 Scott MA, Apperley JF, Jestice HK, Bloxham DM, Marcus RE, Gordon MY. Plastic-adherent progenitor cells in mobilised peripheral blood cell collections. *Blood* 1995 86: 4468-4473.
- 5.1.41 Nawawi H, Samson D, Apperley J, Girgis S. Biochemical bone markers in patients with multiple myeloma. *Clinica Chimica Acta* 1996, 253: 61-77.
- 5.1.42 MacKie N, Dallas DJ, Edwards T, Franklin M, Apperley JF, Russell RGG, Croucher PC. Cloning of a novel membrane-linked metalloproteinase from human myeloma cells. *Biochemistry Journal* 1996, 318: 459-462.
- 5.1.43 Ringden O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen inpatients with grade I acute graft versus host disease. *Leukemia and Lymphoma* 1996, 24: 71-79.
- 5.1.44 Rule SJ, Savage DG, O'Brien SG, Orchard K, McDonald C, Davidson J, Matthey F, Laidlaw ST, Bardhan G, Miller E, Cranfield T, Apperley JF, Goldman JM. Intermediate dose busulfan before autografting for advanced phase chronic myeloid leukaemia. *British Journal of Haematology* 1996, 94: 694-698.
- 5.1.45 Gratwohl A, Hermans J, van Biezen A, Arcese W, de Witte T, Debusscher L, Ernst P, Ferrant A, Frassoni F, Gahrton G, Irondo A, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schmitz N, Siegert W, Torres-Gomez A, Vernant JP, Zwaan F, Apperley JF, for the chronic leukaemia working party of the European Group for Blood and Marrow Transplantation. Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. *British Journal of Haematology* 1996 95: 494 - 500.
- 5.1.46 Bjorkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley JF, Blade J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenti A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma - a retrospective case matched study from the European Group for Blood and Marrow Transplantation. *Blood* 1996 88: 4711-4718.

- 5.1.47 Duell T, van Lint M, Ljungman P, Tichelli A, Socie G, Apperley JF, Weiss M, Cohen A, Nekolla E, Kolb HJ for the EBMT Working Party on Late Effects. Health and functional status of long-term survivors of bone marrow transplantation: a study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. *Annals of Internal Medicine* 1997 126: 184 - 192.
- 5.1.48 Savage D, Blackwell J, Chen F, Rule S, Spencer A, Taylor P, Apperley JF, Goldman JM. Paranasal sinusitis after allogeneic bone marrow transplantation. *Bone Marrow Transplantation* 1997 19: 55 - 60.
- 5.1.49 Chen FE, Owen I, Savage D, Roberts I, Apperley J, Goldman JM, Laffan M. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. *Bone Marrow Transplantation* 1997 19: 491-495.
- 5.1.50 Pfeiffer S, Samson D, Apperley JF, Gooding R. Ex-vivo generation and function of dendritic cells in multiple myeloma. *Biochemical Society Transactions* 1997, 25: 364 S.
- 5.1.51 Ang HA, Apperley JF, Ward KN. Persistence of antibody to human parvovirus B19 after allogeneic bone marrow transplantation: role of prior recipient immunity. *Blood* 1997 89: 4646-4651.
- 5.1.52 Ruutu T, Niederwieser D, Gratwohl A, Apperley JF, on behalf of the EBMT Chronic Leukaemia Working Party. A survey on the prophylaxis and treatment of acute graft versus host disease in Europe. *Bone Marrow Transplantation* 1997 19: 759-764.
- 5.1.53 Scott MA, Apperley JF, Bloxham DM, Marcus RE, Gordon MY. Biological properties of progenitor cells mobilised by granulocyte colony stimulating factor (G-CSF). *British Journal of Haematology* 1997, 97: 474-480.
- 5.1.54 Speiser D, van Biezen A, Hermans J, Starobinski M, Jeannet M, Jacobsen N, Niederwieser D, Gratwohl, Apperley JF. Haploidentical related BMT in patients with chronic myeloid leukaemia. *Bone Marrow Transplantation* 1997, 19: 1197-1204.
- 5.1.55 Devergie A, Apperley JF, Labopin M, Madrigal A, Jacobsen N, Carreras E, Prentice HG, Jouet JP, Kolb HJ, Hertenstein B, Bacigalupo A, Evenson SA, Ljungman P, de Witte T, Reiffers J, Nagler A, Clark RE, Goldman JM, Gratwohl A. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia: impact of HLA D class II matching. *Bone Marrow Transplantation* 1997, 20: 11-20.
- 5.1.56 Pfeiffer S, Gooding R, Apperley JF, Goldschmidt H, Samson D. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. *British Journal of Haematology* 1997, 98: 973-982.
- 5.1.57 Carella AM, Frassoni F, Melo J, Sawyers C, Eaves C, Eaves A, Apperley JF, Tura S, Hehlmann R, Reiffers J, Lerma E, Goldman JM. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. *Hematologica* 1997, 82: 478-495.
- 5.1.58 Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cells: a novel anti-tumour activity. *British Journal of Haematology* 1997, 98: 665-672.
- 5.1.59 van Rhee F, Szydlo RM, Hermans J, Niederwieser D, Jacobsen N, Frassoni F, Arcese W, Gahrton G, Bandini G, Carreras E, Bacigalupo A, de Witte T, Kolb HJ, Link H, Michallet M, Fibbe WE, Ruutu T, Devergie A, Iriando A, Reiffers J, Nielson J, Goldman JM, Apperley JF, Gratwohl A, for the EBMT Chronic Leukaemia Working Party. Long term results after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. *Bone Marrow Transplantation* 1997, 20; 553-560.
- 5.1.60 Savage DG, Szydlo RM, Chase A, Apperley JF, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on actuarial survival curves. *British Journal of Haematology*, 1997, 99: 30-35.
- 5.1.61 de Witte T, van Biezen A, Hermans J, Labopin M, Runde V, Oberg G, Or R, Meloni G, Brunet Mauri S, Bacigalupo A, Apperley JF, Gratwohl A, Gorin NC. Autologous bone marrow transplantation for patients with myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS (sAML): a report from the Chronic and Acute Leukaemia Working Parties of the European Bone Marrow Transplant group (EBMT). *Blood* 1997, 90: 3853-3858.

- 5.1.62 van Rhee F, Savage D, Blackwell, Orchard K, Dazzi F, Feng Lin, Chase A, Bungey J, Apperley JF, Cross R, Szydlo R, Goldman JM. Adoptive immunotherapy for relapse of chronic myeloid leukaemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched marrow donors. *Bone Marrow Transplantation* 1998, 20: 1055-1062.
- 5.1.63 Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter-Noel MP, Bacigalupo A, Jacobsen N, Gahrton G, Carreras E, Kolb HJ, Aul C, Apperley JF. Bone marrow transplantation from HLA-identical siblings as first line treatment in patients with myelodysplastic syndromes or secondary acute myelogenous leukaemia; a European survey. *Bone Marrow Transplantation* 1998, 21: 255-262.
- 5.1.64 Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, Vossen J, Willemze R, Samson D, Gratwohl A, Apperley JF. Unrelated bone marrow donor transplantation in patients with myelodysplasia or secondary AML: an EBMT survey. *Bone Marrow Transplantation* 1998 21: 1213-1216.
- 5.1.65 Cullis JO, Duncombe AS, Dudley JM, Lumley HS, Apperley JF, Smith AG. Acute leukaemia in Jehovah's Witnesses. *British Journal of Haematology* 1998, 100: 664-668.
- 5.1.66 Sati HI, Apperley JF, Greaves M, Lawry J, Gooding R, Russell RGG, Croucher PI. Interleukin-6 is expressed by neoplastic plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. *British Journal of Haematology* 1998, 101: 287-295.
- 5.1.67 Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Varet B, Greinix H, Frickhofen N, Ringden O, Zander A, Apperley JF, Gorin NC, Borkett K, Schwab G, Goebel M, Russell NH, Gratwohl A. Allogeneic bone marrow transplantation versus filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: results of a randomised multicentre trial. *Bone Marrow Transplantation* 1998, 21: 995-1003.
- 5.1.68 Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley JF. Risk assessment for bone marrow transplantation in chronic myeloid leukaemia. *Lancet* 1998, 352: 1087-1092.
- 5.1.69 Kanfer EJ, McGuigan D, Samson DM, Abboudi Z, Abrahamson G, Apperley JF, Chilcott S, Craddock C, Davis J, MacDonald C, Olavarria E, Philpott N, Rustin GJS, Seckl M, Sekhar M, Stern S, Newlands ES. High-dose etoposide with granulocyte colony stimulating factor for mobilisation of peripheral blood progenitor cells: efficacy and toxicity at three dose levels. *British Journal of Cancer* 1998, 78: 928-932.
- 5.1.70 Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Cleeren M, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriando A, Bosi A, Ben Bassat I, Koza V, Gratwohl A, Apperley JF on behalf of the EBMT Chronic Leukaemia Working Party. Incidence, clinical course and outcome of hepatic veno-occlusive disease (VOD) after bone marrow transplantation (BMT): a prospective cohort study of the European Group for Blood and Marrow Transplantation (EBMT). *Blood* 1998, 92: 3599-3604.
- 5.1.71 Guidelines for the clinical use of blood cell separators. A Joint Working Party of the Transfusion and Clinical Haematology Task Forces of the British Committee for Standards in Haematology. *Clinical Laboratory Haematology* 1998, 20: 265-278.
- 5.1.72 Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PI. Anti-tumour activity of bisphosphonates in human myeloma cells. *Leukaemia and Lymphoma*. 1998, 32: 129-138.
- 5.1.73 Gupta D, Bybee A, Cooke F, Giles C, Davies J, McDonald C, Armitage SE, McGuigan D, Lyttelton MPA, Kanfer EJ, Apperley JF, Samson DM. CD34+ selected peripheral blood progenitor cell transplantation after high-dose melphalan and TBI in multiple myeloma tumour cell contamination and outcome. *British Journal of Haematology* 1999, 104: 166-177.
- 5.1.74 Sati HI, Greaves M, Apperley JF, Russell GG, Croucher PI. Expression of interleukin-1 $\beta$  and tumour necrosis factor- $\alpha$  in plasma cells from patients with multiple myeloma. *British Journal of Haematology* 1999, 104: 350-357.



- 5.1.75 Stocchi R, Szydlo R, Craddock C, Apperley JF, Goldman JM, Ward KN. A comparison of prophylactic versus pre-emptive ganciclovir to prevent cytomegalovirus disease after volunteer unrelated donor bone marrow transplantation. *Bone Marrow Transplantation* 1999, 23: 705 - 710.
- 5.1.76 Child FJ, Ratnavel R, Watkins P, Samson D, Apperley JF, Ball J, Taylor P, Russell-Jones R. Extracorporeal photopheresis (ECP) in the treatment of chronic graft versus host disease (GVHD). *Bone Marrow Transplantation* 1999, 23: 881-888.
- 5.1.77 Cohen A, Duell T, Socie G, van Lint MT, Weiss M, Tichelli A, Rovelli A, Apperley JF, Ljungman P. Nutritional status and growth after bone marrow transplantation (BMT) during childhood: EBMT Late-Effects Working Party. *Bone Marrow Transplantation* 1999, 23: 1043-1048.
- 5.1.78 Posthuma EFM, Falkenburg JHF, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, Schipper RF, Schreuder GMT, D'Amaro J, Oudshoorn M, van Biezen JH, Hermans J, Willemze R, Niederwieser D. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukaemia (CML). *Blood* 1999, 93: 3863-3865.
- 5.1.79 Boiron JM, Cahn JY, Meloni G, Carlo-Stella C, Bandini G, Reman O, Milpied N, Apperley JF, Reiffers J for the EBMT Working Party on Chronic Leukaemia. Chronic myeloid leukaemia in first chronic phase not responding to  $\alpha$ -interferon: outcome and prognostic factors after autologous transplantation. *Bone Marrow Transplantation* 1999, 24: 259-264.
- 5.1.80 Gooding R, Bybee A, Coelho E, Gupta D, Cooke F, Samson DM, Apperley JF. Phenotypic and molecular analysis of six human myeloma cell lines. *British Journal of Haematology* 1999, 106: 669-681.
- 5.1.81 Gahrton G, Svensson H, Bjorkstrand B, Apperley JF, Carlson K, Cavo M, Ferrant A, Fouillard L, Gratecos N, Gratwohl A, Guilhot F, Lambertenghi G, Milligan DW, Powles RL, Reiffers J, Samson D, Vernant JP, Volin L, Walvik J for the European Group for Blood and Marrow Transplant. Syngeneic transplantation in multiple myeloma - a case matched comparison of autologous and allogeneic transplantation. *Bone Marrow Transplantation*. 1999, 24: 741-746.
- 5.1.82 Garrett E, Miller ARM, Goldman JM, Melo JV, Apperley JF. Enhanced retroviral gene transfer into CML and normal bone marrow, and CML mobilised peripheral blood CD34+ cells using the recombinant fibronectin fragment CH-296. *British Journal of Haematology* 1999 107: 401-408.
- 5.1.83 Kolb HJ, Socie G, Duell T, van Lint MT, Tichelli A, Apperley JF, Nekolla E, Ljungman P, Jacobsen N, van Weel M, Wick R, Weiss M, Prentice HG. New malignancies in long term survivors of bone marrow transplantation. *Annals of Internal Medicine* 1999, 131: 738-744.
- 5.1.84 Dazzi F, Szydlo RM, Craddock C, Cross NCP, Kaeda J, Chase A, Olavarria E, van Rhee F, Kanfer E, Apperley JF, Goldman JM Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukaemia. *Blood* 2000, 95: 67-71.
- 5.1.85 Garrett E, Miller AM, Goldman JM, Apperley JF, Melo JV. Characterisation of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+env AM12 derived producer cell line. *Virology* 2000, 266: 170-179.
- 5.1.86 Karadag A, Oyajobi BO, Scutt AM, Apperley JF, Russell RGG, Croucher PI. Human myeloma cells promote the synthesis of interleukin-6 by primary human osteoblast-like cells. *British Journal of Haematology*, 2000, 108: 383-390.
- 5.1.87 Garin MI, Apperley JF, Melo JVM. Ex vivo expansion and characterisation of CD34+ cells from normal bone marrow, mobilised peripheral blood, CML-bone marrow and CML-peripheral blood. *European Journal of Hematology* 2000, 64: 85-92.
- 5.1.88 Michallet M, Thiebaut A, Apperley JF. Peripheral blood progenitor cell mobilisation and transplantation after fludarabine therapy in chronic lymphocytic leukaemia. *British Journal of Haematology* 2000, 108: 595-601.
- 5.1.89 Olavarria E, Kanfer E, Szydlo R, O'Brien S, Craddock C, Apperley JF, Goldman JM. High dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a

single centre experience. *British Journal of Haematology* 2000, 108: 769-777.

5.1.90 Olavarria E, Parker S, Craddock C, Philpott N, Tiniakou M, Chase A, Kanfer E, Apperley JF, Goldman JM. Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization. *Haematologica* 2000, 85: 647-652.

5.1.91 Guglielmi C, Arcese W, Hermans J, Bacigalupo A, Bandini G, Bunjes D, Carreras E, Devergie A, Frassoni F, Goldman JM, Gratwohl A, Kolb HJ, Iori AP, Niederwieser D, Prentice HG, de Witte T, Apperley JF. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant. An EBMT retrospective analysis. *Blood*. 2000, 95: 3328-34.

5.1.92 Posthuma EFM, Falkenburg JHF, Apperley JF, Gratwohl A, Hertenstein B, Schipper RF, GMT Schreuder GMT, D'Amaro J, Oudshoorn M, van Biezen A, Hermans J, Willemze R, Roosnek E, Niederwieser D. on behalf of the Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukaemia (CML). *Leukemia* 2000, 14: 859-862.

5.1.93 Rivas C, Chandler P, Simpson E, Melo JV, Apperley JF. Absence of in vitro or in vivo bystander effects in TK-transduced murine T-lymphocytes. *Cancer Gene Therapy* 2000 7: 954-62.

5.1.94 Craddock C, Szydlo RM, Klein JP, Dazzi F, Olavarria E, van Rhee F, Pocock C, Cwynarski K, Apperley JF, Goldman JM. Estimating leukemia free survival after allografting for chronic myeloid leukemia: A new method that takes account of patients who relapse and are restored to complete remission. *Blood* 2000 96: 86-90.

5.1.95 de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, Ruutu T, Ljungman P, Gratwohl A, Runde V, Niederwieser D, van Biezen A, Devergie A, Cornelissen J, Jouet JP, Arnold R, Apperley JF. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. *British Journal of Haematology* 2000 110: 620-630.

5.1.96 Dazzi F, Szydlo RM, Cross NCP, Craddock C, Kaeda J, Kanfer E, Cwynarski K, Olavarria E, Yong A, Apperley JF, Goldman JM. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. *Blood* 2000 96: 2712-2716.

5.1.97 Olavarria E, Hassan M, Eades A, Nilsson C, Timms A, Matthews J, Craddock C, Kanfer E, Apperley JF, Goldman JM. A phase I study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. *Leukemia* 2000 14: 1954-1959.

5.1.98 Craddock C, Bardy P, Kreiter S, Johnson R, Apperley JF, Marks D, Huber C, Kolbe K, Goulding R, Lawler M, Goldman JM, Hughes T, Derigs G. Engraftment of T cell depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. *British Journal of Haematology* 2000 111: 797-800.

5.1.99 Craddock C, Szydlo R, Dazzi F, Olavarria E, Czynwarski K, Yong A, Brookes P, de la Fuente J, Kanfer E, Apperley JF, Goldman JM. CMV serostatus is a major determinant of outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored GVHD prophylaxis. *British Journal of Haematology* 2001, 112: 228-236.

5.1.100 Garin M, Garrett E, Tiberghien P, Apperley JF, Chalmers D, Melo JV, Ferrand C. Molecular mechanisms for ganciclovir resistance in human T-lymphocytes transduced with a retroviral vector carrying the herpes simplex virus thymidine kinase gene. *Blood* 2001 97: 122-129.

5.1.101 Olavarria E, Kanfer E, Szydlo RM, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, Craddock C, Apperley JF, Cross NCP, Goldman JM. Early detection of BCR/ABL transcripts by quantitative RT-PCR predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. *Blood* 2001, 97: 1560-1565.

5.1.102 Elizaga J, Olavarria E, Apperley JF, Goldman JM, Ward KN. Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. *Clinical Infectious Diseases* 2001 32: 413-418.

5.1.103 Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley JF, Goldman JM, Craddock C,

Moss PAH. Direct visualisation of cytomegalovirus specific T-cell reconstitution following allogeneic bone marrow transplantation. *Blood* 2001 97: 1232-1240.

5.1.104 Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley JF, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Blade J, Lenhoff S, Iriando A, Carlson K, Sweetenham J, Volin L, Littlewood T, Goldstone AH, San Miguel J, de Witte T, Gahrton G.  $\alpha$ -interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplant. *Bone Marrow Transplantation* 2001 27: 511-515.

5.1.105 Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Bjorkstrand B, Blade J, Cornelissen J, de Laurenzi A, Facon T, Ljungman P, Michallet M, Niederwieser D, Powles R, Reiffers J, Russell NH, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck L, Vernant JP, Willemze R, Volin L. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-1993 and 1994-1998 at EBMT centres. *British Journal of Haematology* 2001 113: 209-216.

5.1.106 Pocock CF, Lucas GF, Giles C, Vassilou G, Cwynarski K, Rezvani K, Apperley JF, Goldman JM. Immune neutropenia associated with anti-human neutrophil antigen 2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony-stimulating factor. *British Journal of Haematology* 2001 113: 483-485.

5.1.107 Rivas C, Miller ARM, Collado M, Lam EWK, Apperley JF, Melo J. BCR-ABL expressing cells transduced with the HSV-TK gene die by apoptosis upon treatment with ganciclovir. *Molecular Therapy* 2001 3: 642-652.

5.1.108 Salooja N, RM Szydlo, G Socie, B Rio, R Chatterjee, P Ljungman, MT Van Lint, R Powles, G Jackson, M Hinterberger-Fischer, HJ Kolb, JF Apperley. on behalf of the Late Effects Working Party of the EBMT. Pregnancy following peripheral blood or marrow transplantation. *Lancet* 2001 358: 271-276.

5.1.109 Clark RE, Hermans J, Madrigal A, Nachbaur D, Kropshofer G, Gratwohl A, Apperley JF, Niederwieser D. for the Chronic Leukaemia Working Party of the European Group of Blood and Bone Marrow Transplantation (EBMT). HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease following HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia. *British Journal of Haematology* 2001 114: 36-41.

5.1.110 Pocock CF, Szydlo RM, Davis JD, De La Fuente J, Craddock C, Cwynarski K, Olavarria E, Rezvani K, Kanfer E, Apperley JF, Goldman JM. Stem cell transplantation for chronic myeloid leukemia: the role of infused marrow cell dose. *The Hematology Journal* 2001 2: 265-271.

5.1.111 Chalmers D, Ferrand C, Apperley JF, Melo JV, Ebeling S, Newton I, Duperrier A, Hagenbeek A, Garrett E, Tiberghien P, Garin MI Elimination of the truncated message from the Herpes simplex virus thymidine kinase suicide gene. *Molecular Therapy* 2001 4: 146-148.

5.1.112 Olavarria E, Child F, Woolford A, Whittaker S, Davis JG, McDonald C, Chilcott S, Spittle M, Grieve R, Stewart S, Apperley JF, Russell-Jones R. T-cell depletion and autologous stem cell transplantation in the management of tumor stage mycosis fungoides with peripheral blood involvement. *British Journal of Haematology* 2001 114: 624-631.

5.1.113 Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in bone marrow transplant patients. *Cytotherapy* 2001 3: 261-267.

5.1.114 Russell-Jones R, Child F, Olavarria E, Whittaker S, Spittle M, Apperley JF. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. *The Annals of the New York Academy of Sciences*. 2001 941: 147-154

5.1.115 Mughal T, Yong A, Szydlo RM, Dazzi FG, Olavarria E, van Rhee F, Kaeda J, Cross NCP, Craddock C, Kanfer E, Apperley JF, Goldman JM. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. *Brit J Haematol* 2001, 115: 569-574.

5.1.116 Gillmore JD; Apperley JF; Lachmann HJ; Barrett AJ; Madhoo S; Pepys MB; Hawkins PN. Combination chemotherapy for systemic AL amyloidosis. *Amyloid* 2001. 8: 72-73

- 5.1.117 Gratwohl A, Herman J, Niederwieser D, van Biezen A, van Houwelingen HC, Apperley JF for the Chronic Leukaemia Working Party of the EBMT. Female donors influence transplant related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. *The Hematology Journal* 2001 2: 363-370.
- 5.1.118 De Witte T, Pikkemaat F, Hermans J, van Biezen A, MacKinnan S, Cornelissen J, Gratwohl A, Delforge M, Iriando A, Kuentz M, Harousseau J, Fauser A, Wandt H, Runde V, Niederwieser D, Apperley JF. Genotypically non-identical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. *Leukemia* 2001 15: 581-586
- 5.1.119 Cwynarski K, Goulding R, Pocock C, Dazzi F, Craddock C, Kaeda K, Olavarria E, Kanfer E, Apperley J, Lawler M, Goldman JM. Immune haemolytic anaemia following T-cell depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. *Bone Marrow Transplantation* 2001 28: 581-586.
- 5.1.120 Sauce D, Bodinier M, Garin MI, Petracca B, Tonnelier N, Duperrier A, Melo JV, Apperley JF, Ferrand C, Hervé P, Lang F, Tiberghien P, Robinet E. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-EBV potential through both culture-dependent and selection process-dependent mechanisms. *Blood* 2002 99: 1165-1173.
- 5.1.121 Hassertjian RP, Boecklin F, Parker S, Chase A, Dhar S, Zaiac M, Olavarria E, Lampert I, Henry K, Apperley JF, Goldman JM. STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. *Hematopathology* 2002, 117: 360-367.
- 5.1.122 Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, Olavarria E, Kanfer E, Goldman JM. Factors impacting on duration of survival after onset of blastic transformation of chronic myeloid leukaemia. *Blood* 2002, 99: 2304-2309.
- 5.1.123 Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NCP, Goldman JM. Chronic Myeloproliferative Diseases Involving Rearrangements of the Platelet Derived Growth Factor Receptor Beta (PDGFRB) Showing Rapid Responses to the Tyrosine Kinase Inhibitor STI571 (Imatinib Mesylate). *New England Journal of Medicine* 2002 347:481-487.
- 5.1.124 Olavarria E, Reiffers J, Boque C, Sureda A, Capria S, Michallet M, Clark R, Blaise D, Carella A, Cahn JY, Jouet JP, Rizzoli V, Van Biezen A, Gratwohl A, Goldman JM, Niederwieser D and Apperley JF for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). The cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia. *British Journal of Haematology* 2002, 118; 762-770.
- 5.1.125 Olavarria E, Craddock C, Dazzi F, Marin D, Markt S, Apperley JF, Goldman JM. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. *Blood* 2002 99:3861-2
- 5.1.126 Marin D, Markt S, Bua M, Armstrong L, Goldman JM, Apperley JF, Olavarria E. The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. *Haematologica* 2002 87:979-88
- 5.1.127 Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russell N, Apperley JF, Gorin NC, Szer J, Bradstock K, Buzyn A, Clark P, Borkett K, Gratwohl A; European Group for Blood and Marrow Transplantation. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. *Blood* 2002 100:761-7.
- 5.1.128 Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF, Schattenberg A, Kolb HJ, Ljungman P, Devergie A, Bacigalupo A, Gomez M, Michallet M, Elmaagacli A Gratwohl A, Apperley JF, Niederwieser D on behalf of the Chronic Leukaemia Working party of the EBMT. Donor lymphocyte infusion for relapsed chronic myelogenous leukaemia: prognostic relevance of the initial cell dose. *Blood* 2002, 100:397-405.
- 5.1.129 Ruutu T, Hermans J, Niederwieser D, Gratwohl A, Kiehl M, Volin L, Bertz H, Ljungman P, Spence D, Verdonck LF, Prentice HG, Bosi A, du Toit CE, Brinch L, Apperley JF on behalf of the EBMT Chronic Leukaemia Working Party. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: A survey of the

European Group for Blood and Marrow Transplantation (EBMT). *British Journal of Haematology*, 2002 118;1112-1119.

5.1.130 Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H, Gluckman E, Friedrich W, Cordonnier C, Socie G, Tyndall A, Niethammer D, Ljungman P, Gratwohl A, Apperley J, Niederwieser D, Bacigalupo A; European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. *Bone Marrow Transplantation* 2002, 29: 639-646.

5.1.131 Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A, Schattenberg A, Frassoni F, Guglielmi C, Iacobelli S, Michallet M, Kolb HJ, Ruutu T, Niederwieser D. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. *Blood* 2002 100:3877-3886.

5.1.132 Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM, Stauss HJ. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. *Blood* 2002 100:3835-7.

5.1.133 Markt S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, Melo VAS, Kotzampaliris P, Dazzi F, Olavarria E, Apperley JF, Goldman JM. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. *Haematologica* 2003, 88: 246-253.

5.1.134 Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A. Autologous stem cell transplantation in multiple myeloma: improved survival in non-secretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single center experience in 127 patients. *Bone Marrow Transplantation* 2003, 31: 163-170.

5.1.135 Marin D, Markt S, Bua M, Szydlo RM, Francheschino A, Nathan I, Foot, N, Crawley C, Na Nakorn T, Olavarria E, Lennard A, Neylon A, O'Brien SG, Goldman JM, Apperley JF. Prognostic factors for patients with chronic myeloid leukemia in chronic phase treated with imatinib mesylate after failure of interferon alpha. *Leukemia* 2003 17: 1448-1453

5.1.136 Seaton ED, Szydlo RM, Kanfer E, Apperley JF, Russell-Jones R. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. *Blood*. 2003 102: 1217-23.

5.1.137 Orlent H, Crawley C, Cwynarski K, Dina R, Apperley J. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 2003 32:115-7.

5.1.138 Goldman JM, Marin D, Olavarria E, Apperley JF. Clinical decisions for chronic myeloid leukemia in the imatinib era. *Semin Hematol*. 2003 40 (Suppl 3):98-103

5.1.139 Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A. Soluble receptor activator of nuclear factor {kappa}B ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. *Blood*. 2003 102: 1064-9.

5.1.140 Cwynarski K, Roberts IA, Iacobelli S, Van Biezen A, Brand R, Devergie A, Vossen JM, Aljurf M, Arcese W, Locatelli F, Dini G, Niethammer D, Niederwieser D, Apperley JF. Stem cell transplantation for chronic myeloid leukemia in children. *Blood*. 2003 102: 1224-31.

5.1.141 Marin D, Markt S, Szydlo R, Klein JP, Bua M, Foot N, Olavarria E, Shepherd P, Kanfer E, Goldman JM, Apperley JF. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. *Lancet*. 2003 362:617-9

5.1.142 Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1 ) correlate with the extent of bone disease and survival of patients with multiple myeloma. *British Journal of Haematology* 2003, 123: 106-109.

5.1.143 Zino E, Frumento G, Markt S, Sormani MP, Ficara F, Di Terlizzi S, Parodi AM, Sergeant R, Martinetti M, Bontadini A, Bonifazi F, Lisini D, Mazzi B, Rossini S, Servida P, Ciceri F, Bonini C, Bandini G, Locatelli F, Apperley JF, Bacigalupo A, Ferrara GB, Bordignon C, Fleischhauer K. A T cell epitope encoded by a subset of

HLA-DP $\beta$ 1 alleles determines non-permissive mismatches for hematological stem cell transplantation. *Blood* 2003 103:1417-24

5.1.144 Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russell N, Apperley J, Szer J, Bradstock K, Buzyn A, Matcham J, Gratwohl A, Schmitz N; European Group for Blood and Marrow Transplantation (EBMT). Differences between graft product and donor side effects following bone marrow or stem cell donation. *Bone Marrow Transplant*. 2003 32: 873-80.

5.1.145 Avery S, Nadal E, Marin D, Olavarria E, Kaeda J, Vulliamy T, Brito Babapulle F, Goldman JM, Apperley JF. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. *Leuk Res*. 2004; 28 Suppl 1:75-7.

5.1.146 Politou M, Terpos E, Nadal E, Crawley C, Apperley JF, Rahemtulla A. Prolonged effect of reduced intensity conditioning (RIC) allogeneic transplantation for multiple myeloma on biochemical markers of bone remodelling and osteoclast function: report of a case *Haema* 7:87-91 2004

5.1.147 Russell NH, Szydlo R, McCann S, Potter MN, Craddock C, Towilson K, Apperley JF. The use of a national transplant registry to benchmark transplant outcome for patients undergoing autologous and allogeneic stem cell transplantation in the United Kingdom and Ireland. *British Journal of Haematology*. 2004, 124: 499-503.

5.1.148 Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E, Kanfer E, Goldman JM, Apperley JF, Rahemtulla. Autologous stem cell transplantation normalizes abnormal bone remodelling and sRANKL/osteoprotegerin ration in patients with multiple myeloma. *Leukemia*. 2004 18:1420-6.

5.1.149 Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). *British Journal of Haematology* 2004 126:686-9

5.1.150 Nadal E, Fowler A, Kanfer E, Apperley J, Goldman J, Dazzi F. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. *Exp Hematol*. 2004 32:218-23.

5.1.151 Bakkus MHC, Bouko Y, Samson D, Apperley JF, Thielemans K, van Camp B, Benner A, Goldschmidt H, Moos M, Cremer FW. Post transplantation tumour load in bone marrow assessed by quantitative ASO-PCR is a prognostic parameter in multiple myeloma. *British Journal of Haematology* 2004 126: 665-674.

5.1.152 Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J, Andreasson C, Bua M, Olavarria E, Rahemtulla A, Dazzi F, Kanfer E, Goldman JM, Apperley JF. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. *Leukemia*. 2005 19:507-12

5.1.153 Passweg J, Orchard K, Buergi A, Gratwohl A, Powles R, Goldman J, Apperley J, Mehta J. Autologous/syngeneic stem cell transplantation to treat refractory graft versus host disease. *Bone Marrow Transplant* 2004. 34: 995-998.

5.1.154 Gratwohl A, Baldomero H, Labar B, Apperley JF, Urbano-Ispizua A for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Evolution of hematopoietic stem cell transplantation (HSCT) in eastern and western Europe from 1990 to 2003: a report from the EBMT Activity Survey. *Croatian Medical Journal* 2004 45: 689-694.

5.1.155 Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. *Cancer*. 2005 103:1850-5

5.1.156 Gahrton G, Iacobelli S, Apperley J, Bandini G, Björkstrand B, Bladé J, Boiron JM, Cavo M, Cornelissen J, Corradini P, Kröger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander A, Niederwieser D. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. *Bone Marrow Transplantation* 2005 35: 609-617.

- 5.1.157 Stem Cell Trialists Group. Allogeneic peripheral blood stem cell vs. bone marrow transplantation in the management of hematological malignancies: an individual patient data meta-analysis of 9 randomized trials and 1,111 patients. *Journal of Clinical Oncology* 2005 23:5074-5087
- 5.1.158 Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russell N, Apperley JF, Szer J, Bradstock K, Buzyn A, Schlegelberger B, Matcham J, Gratwohl A. Transplantation of filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. *Hematologica* 2005 90: 643-648
- 5.1.159 Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson DM, Apperley JF. Plasmacytoma relapses in the absence of systemic progression post high dose therapy for multiple myeloma. *European Journal of Haematology* 2005 75 376-383.
- 5.1.160 Ruutu T, Corradini P, Gratwohl A, Holler E, Apperley J, Dini G, Rocha V, Schmitz N, Socie G, Niederwieser D. Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant.* 2005 35:121-4.
- 5.1.161 Elliot V, Marin D, Horncastle D, Elderfield K, Apperley JF, Lampert IA, Naresh K. Percentage of CD34 cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count. *Br J Haematol.* 2005 130:460-1.
- 5.1.162 Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, Juliusson G, Ahlberg L, Nagler A, Shimoni A, Sureda A, Boiron JM, Einsele H, Chopra R, Carella A, Cavenagh J, Gratwohl A, Garban F, Zander A, Bjorkstrand B, Niederwieser D, Gahrton G, Apperley JF; Chronic Leukaemia Working Party of the EBMT. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. *Blood.* 2005 105:4532-9.
- 5.1.163 Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss HJ. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene transduced human T cells. *Blood* 2005 106:3062-7.
- 5.1.164 Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF. Outcomes of reduced intensity transplantation for chronic myeloid leukaemia: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. *Blood.* 2005 106:2969-76.
- 5.1.165 Yong A, Szydlo R, Goldman JM, Apperley JF, Melo JV. Molecular profiling of CD34+ cells identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival in CML patients. *Blood.* 2006 107:205-12.
- 5.1.166 Khorashad JS, Anand M, Marin D, Saunders S, Al-Jabhry T, Iqbal A, Margerison S, Melo JV, Goldman JM, Apperley JF, Kaeda J. The presence of a bcr-abl mutant allele in CML does not always explain clinical resistance to imatinib. *Leukaemia* 2006 20:658-63.
- 5.1.167 Kaeda J, O'Shea D, Szydlo RM, Olavarria E, Dazzi F, Marin D, Saunders S, Khorashad JS, Cross NC, Goldman JM, Apperley JF. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplant for chronic myeloid leukemia: An attempt to define patients who may not require further therapy. *Blood.* 2006 107:4171-6.
- 5.1.168 Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, dini G, Einsele H, Gratwohl A, Madrigal A, Niederwieser D, Passweg, J, Rocha V, Saccardi R, Schouten H, Schmitz N, Socie G, Sureda A, Apperley JF. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. *Bone Marrow Transplantation* 2006 37: 439-449.
- 5.1.169 Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). *Haematologica.* 2006 91:513-21.

- 5.1.170 O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation for: a single-centre experience in 211 patients. *Bone Marrow Transplant.* 2006 37:731-7
- 5.1.171 Politou M, Naresh K, Terpos E, Crawley C, Lampert I, Apperley JF, Rahemtulla A. Anti-angiogenic effect of bortezomib in patients with multiple myeloma. *Acta Haematol.* 2005;114:170-3.
- 5.1.172 Gordon MY, Levicar N, Bachellier P, Dimarakis I, Al-Allaf F, M'hamdi H, Thalji T, Welsh JP, Marley SB, Davis J, Dazzi F, Marelli-Berg F, Tait P, Playford R, Jiao L, Jensen S, Nicholls JP, Ayav A, Nohandani M, Farzaneh F, Gaken J, Dodge R, Alison M, Apperley JF, Lechler R, Habib NA. Characterisation and clinical application of human CD34+ stem/progenitor cell populations mobilised into the blood by G-CSF. *Stem Cells.* 2006 24:1822-30
- 5.1.173 David M, Cross NCP, Burgstaller S, Chase A, Curtis C, Dang R, Gardembas M, Goldman JM, Grand F, Hughes G, Huguet F, Lavender L, McArthur GA, Mahon FX, Massimini G, Melo JV, Rousselot P, Russell-Jones RJ, Seymour JF, Smith G, Stark A, Waghorn K, Nikolova Z, Apperley JF. Durable responses to imatinib in patients with PDGFRB fusion gene positive and bcr-abl negative chronic myeloproliferative disorders. *Blood.* 2006 109:61-4
- 5.1.174 Duarte RF, Pamphilon D, Cornish J, Shaw BE, Samson D, Craddock C, Marks D, Mufti GJ, Powles RL, Apperley JF, Madrigal JA, Goldman JM. Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005. *Bone Marrow Transplant* 37:901-908.
- 5.1.175 Perz JB, Rahemtulla A, Giles C, Szydlo RM, Davis J, Gopaul D, Gillmore J, Mathias CJ, Hawkins PN, Apperley JF. Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. *Bone Marrow Transplant* 2006 37:937-43.
- 5.1.176 Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia Net. *Blood.* 2006 108:1809-20.
- 5.1.177 Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. *Br J Haematol.* 2006 134:385-90.
- 5.1.178 Greinix HT, Socié G, Bacigalupo A, Holler E, Edinger MG, Apperley JF, Schwarz T, Ullrich SE, Albert ML, Knobler RM, Peritt D, Ferrara JLM. Meeting Report: Assessing the potential role of photopheresis in hematopoietic stem cell transplant. *Bone Marrow Transplantation* 2006 38:265-73.
- 5.1.179 Bensinger WI, Al-Jurf M, Annasetti C, Djulbegovic B, Kumar A, Soares HP, Apperley JF, Baynes R, Matcham J, Blaise D, Mohty M, Clarke M, Colcol E, Sahovic E, Cornelissen JJ, Van der Holt B, Couban S, Cutler C, Gratwohl A, Heldal D, Hills RK, Wheatley K, Hozo I, Kuentz M, Lipton JH, Miranda ECM, de Souza CA, Vigorito AC, Morton J, Panzarella T, Powles R, Sirohi B, Richards S, Schmitz N, Simpson DR Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs. bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. *Bone Marrow Transplantation* 2006 38:539-46.
- 5.1.180 Perz JB, Kristen AV, Rahemtulla A, Parameshwar J, Sack F-U, Apperley JF, Goldschmidt H, Katus HA, Dengler TJ. Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. *Clinical Research in Cardiology* 2006 95:1-4.
- 5.1.181 Daikeler T, Kotter I, Bocelli Tyndall C, Attarbaschi A, Apperley J, Guardiola P, Gratwohl A, Jantunen E, Marmont A, Porretto F, Musso M, Maurer B, Rinaldi N, Saccardi R, Tyndall A. Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polycondritis- A retrospective analysis of patients



recorded to the European Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) databases and a review of the literature. *Ann Rheum Dis.* 2007 66:202-7.

5.1.182 Gorin NC, Fliedner TM, Gourmelon P, Ganser A, Meineke V, Sirohi B, Powles R, Apperley J. Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. *Ann Hematol.* 2006 85:671-9.

5.1.183 Perz JB, Khorashad JS, Marin D, Apperley JF, Olavarria E. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. *Haematologica.* 2006 91:1145-6.

5.1.184 Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. *Blood.* 2006 109: 2303-2309.

5.1.185 Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. *Blood.* 2006 109: 3207-3210.

5.1.186 Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced intensity conditioning for myeloma: lower non-relapse mortality but higher relapse rates compared to myeloablative conditioning *Blood.* 2006 109: 3588-3594.

5.1.187 Weisdorf D, Apperley J, Gourmelon P, Gorin NC, Wingard J, Chao N. Radiation emergencies: evaluation, management, and transplantation. *Biol Blood Marrow Transplant.* 2007 13 Suppl 1:103-6.

5.1.188 Nadal E, Garin M, Kaeda J, Apperley JF, Lechler R, Dazzi F. Increased frequencies of CD4<sup>+</sup>CD25<sup>high</sup> Tregs correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. *Leukemia* 2007 21: 1-8. *Leukemia.* 2007 21:472-9.

5.1.189 Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. *Blood.* 2007 109: 4143-4150

5.1.190 Jovanovic J, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Bapapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFR $\alpha$  positive chronic eosinophilic leukemia. *Blood.* 2007 109: 4635-4640.

5.1.191 Mohty M, Yong ASM, Szydlo RM, Apperley JF, Melo JV. The polycomb group *BMI-1* gene is a molecular marker for predicting prognosis of chronic myeloid leukaemia. *Blood.* 2007 110: 380-383

5.1.192 Fozza C, Szydlo RM, Abdel-Rehim MM, Nadal E, Goldman JM, Apperley JF, Dazzi F. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. *Br J Haematol.* 2007 136:833-6.

5.1.193 Simula MP, Markt S, Fozza C, Kaeda J, Szydlo RM, Nadal E, Bua M, Rahemtulla A, Kanfer E, Marin D, Olavarria E, Goldman JM, Apperley JF, Dazzi F. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. *Leukemia.* 2007 21: 943-948

5.1.194 Elliot V, Marin D, Horncastle D, Elderfield K, Howard J, Apperley JF, Lampert IA, Naresh KN. Total CD34<sup>+</sup> cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment. *Histopathology.* 2007 50: 810-812

- 5.1.195 Nadal E, Kaeda J, Apperley JF, Lechler R, Dazzi F. Increased CD4+CD25high+regulatory T-cell are associated with disease relapse after allogeneic stem cell transplantation (SCT) for chronic myeloid leukaemia (CML). *Biol Blood Marrow Tr* 2007 13:15-15.
- 5.1.196 Perz JB, Marin D, Szydlo RM, Giles C, Olavarria E, Williams G, Apperley JF. Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation. *Leuk Res* 2007 31: 1433-1436.
- 5.1.197 Knop S, Hebart H, Gratwohl A, Kliem C, Faul C, Holler E, Apperley J, Kolb HJ, Schaefer A, Niederwieser D, Einsele H. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. *Leukemia*. 2007 21:1830-3.
- 5.1.198 Gabriel IH, Olavarria E, Jones RR, Whittaker S, Chaidos A, Apperley JF. Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides. *Bone Marrow Transplant*. 2007 40:401-3.
- 5.1.199 Bourhis JH, Samson DM, Apperley JF, Bakkus M, Gahrton G. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study *Haematologica* 2007 92:1083-90.
- 5.1.200 Brazma D, Grace C, Howard J, Melo JV, Holyoke T, Apperley JF, Nacheva EP. Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. *Genes Chromosomes Cancer* 2007 46: 1039-50.
- 5.1.201 Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper K, Lennard A, Pallan L, Arrazi K, Perz J, O'Shea D, Goldman J, Apperley JF, Craddock C. Post-transplant imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced intensity allografts for chronic myeloid leukemia. *Blood* 2007 110:4614-7.
- 5.1.202 Perz JB, Szydlo R, Sergeant R, Sanz J, O'Shea D, Khan T, Davey N, Loaiza S, Davis J, Apperley JF, Olavarria E. Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab. *Transpl Immunol* 18: 179-185
- 5.1.203 le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YI, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. *Blood*. 2008 111: 1834-1839
- 5.1.204 Gratwohl A, Baldomero H, Schwenedener A, Gratwohl M, Apperley JF, Niederwieser D, Frauendorfer K. Predictability of hematopoietic stem cell transplantation rates. *Haematologica*. 2007 92:1679-86.
- 5.1.205 Gratwohl A, Baldomero H, Rocha V, Apperley JF, Niederwieser D. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. *Bone Marrow Transplant*. 2008 41:687-705.
- 5.1.206 Levicar N, Pai M, Habib NA, Tait P, Jiao LR, Marley SB, Davis J, Dazzi F, Smadja C, Jensen SL, Nicholls JP, Apperley JF, Gordon MY. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. *Cell Prolif*. 2008 41 Suppl 1:115-25.
- 5.1.207 Gabriel I, Gazzard B, Chaidos A, Giles C, Bower M, Nelson M, Kanfer E, Apperley JF. A long-term durable remission with high dose therapy autologous stem cell transplant for Stage IVB HIV-associated Hodgkins disease. *AIDS* 2008 22:539-40.
- 5.1.208 Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG, de Melo V, Babb A, de Lavallade H, Olavarria E, Marin D, Goldman JM, Apperley JF, Kaeda JS. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. *Blood* 2008 111: 2378-2381.

- 5.1.209 Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot H, Rosti G, Apperley JF. The effects of Imatinib on pregnancy outcome. *Blood* 2008 111:5505-8.
- 5.1.210 Heinrich MC, Joensuu H, Demetri GD, Corless C, Apperley JF, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur G for the Imatinib Target Exploration Consortium Study B2225. Phase II open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. *Clin Cancer Res.* 2008 14:2717-25.
- 5.1.211 De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid A, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis. *J Clin Oncol.* 2008 26:3358-63.
- 5.1.212 Khorashad J, Milojkovic D, Marin D, Foroni L, Goldman JM, Apperley JF, Reid A. A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukemia. *J Clin Pathol.* 2008 61:863-5.
- 5.1.213 Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. *Leukemia* 2008 22:1200-6.
- 5.1.214 Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase II randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host *Blood* 112:2667-74.
- 5.1.215 Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levičar N, Tait P, Scott M, Marley SB, Justice K, Glibetic M, Bansi D, Khan SA, Kyriakou D, Rountas C, Thillainayagam A, Nicholls JP, Jensen S, Apperley JF, Gordon MY, Habib NA. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. *Am J Gastroenterol.* 2008 103:1952-8.
- 5.1.216 Virgili A, Brazma D, Reid AG, Howard-Reeves J, Valganon M, Chanalaris A, De Melo VA, Marin D, Apperley JF, Grace C, Nacheva E. FISH mapping of Philadelphia negative BCR/ABL1 positive CML. *Mol Cytogenet.* 2008 1:14.
- 5.1.217 Mohty M, Szydlo RM, Yong AS, Apperley JF, Goldman JM, Melo JV. Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. *Blood.* 2008 112:2163-6.
- 5.1.218 Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. *J Clin Oncol.* 2008 26:4806-13.
- 5.1.219 Iacobelli S, Apperley J, Morris C. Assessment of the role of timing of second transplantation in multiple myeloma by multistate modeling. *Exp Hematol.* 2008 36:1573-7.
- 5.1.220 Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. *Bone Marrow Transplant.* 2008 42:783-9.
- 5.1.221 Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda J, Goldman JM, Apperley JF. European Leukemia Net criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. *Blood.* 2008 112:4437-44.
- 5.1.222 Walz C, Score J, Mix J, Cilloni D, Roche-Lestienne C, Yeh RF, Wiemels JL, Ottaviani E, Erben P, Hochhaus A, Baccarani M, Grimwade D, Preudhomme C, Apperley J, Martinelli G, Saglio G, Cross NC, Reiter A. The molecular anatomy of the FIP1L1-PDGFR $\alpha$  fusion gene. *Leukemia.* 2009 23:271-8.

- 5.1.223 Halter J, Kodera Y, Urbano Ispizua A, Greinix HT, Schmitz N, Favre G, Baldomero H, Niederwieser D, Apperley JF, Gratwohl A, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. *Haematologica* 2009 94:94-10.
- 5.1.224 Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K, Niederwieser D; Joint Accreditation Committee of the International Society for Cellular Therapy; European Group for Blood and Marrow Transplantation. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. *Bone Marrow Transplant*. 2009 43:275-91.
- 5.1.225 Reid AG, De Melo VA, Elderfield K, Clark I, Marin D, Apperley J, Naresh KN. Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics. *Leuk Res*. 2009 33:418-25.
- 5.1.226 Marin D, Khorashad JS, Foroni L, Milojkovic D, Szydlo R, Reid AG, Rezvani K, Bua M, Goldman JM, Apperley JF. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? *Br J Haematol* 2009 145:373-5
- 5.1.227 Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, Turchetto L, Colombi S, Bernardi M, Peccatori J, Pescarollo A, Servida P, Magnani Z, Perna SK, Valtolina V, Crippa F, Callegaro L, Spoldi E, Crocchiolo R, Fleischhauer K, Ponzoni M, Vago L, Rossini S, Santoro A, Todisco E, Apperley J, Olavarria E, Slavin S, Weissinger EM, Ganser A, Stadler M, Yannaki E, Fassas A, Anagnostopoulos A, Bregni M, Stampino CG, Bruzzi P, Bordignon C. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. *Lancet Oncol*. 2009 10:489-500.
- 5.1.228 Cordonnier C, Labopin M, Chesnel V, Ribaud P, De La Camara R, Martino R, Ullmann AJ, Parkkali T, Locasciulli A, Yakouben K, Pauksens K, Einsele H, Niederwieser D, Apperley J, Ljungman P; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. *Clin Infect Dis*. 2009 48:1392-401
- 5.1.229 Clare S, Mank A, Stone R, Davies M, Potting C, Apperley JF. Management of related donor care: a European survey. *Bone Marrow Transplant* 2009 45:97-101
- 5.1.230 Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, et al. Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. *J Clin Oncol*. 2009 27:3472-9.
- 5.1.231 Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M. Defining the intensity of conditioning regimens: working definitions. *Biology of Blood and Marrow Transplantation*. 2009 12:1628-33.
- 5.1.232 Morris T, Drake MB, Apperley JF, Iacobelli S, Niederwieser D, van Biezen A, Bjorkstrand B, Gahrton G. Efficacy and Outcome of Autologous Transplantation in Rare Myelomas. *Clin Lymphoma Myeloma* 9 Feb 2009
- 5.1.233 Pamphilon D, Apperley JF, Samson D, Slaper-Cortenbach I, McGrath E JACIE Accreditation in 2008: demonstrating excellence in stem cell transplantation. *Hematology/Oncology and Stem Cell Therapy* 2009;2:311-9
- 5.1.234 Uprichard J, Dazzi F, Apperley JF, Laffan MA Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides. *Haemophilia* 2009 16:143-7
- 5.1.235 Gratwohl A, Schwendener A, Baldomero H, Gratwohl M, Apperley JF, Niederwieser D, Frauendorfer K. Changes in use of hematopoietic stem cell transplantation; a model for diffusion of medical technology. *Haematologica* 2009 95:637-43
- 5.1.236 Khorashad JS, Wagner S, Greener L, Marin D, Reid A, Milojkovic D, Patel H, Willimott S, Rezvani K, Gerrard G, Loaiza S, Davis J, Goldman J, Melo J, Apperley J, Foroni L. The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. *Haematologica*. 2009 94:861-4.

- 5.1.237 Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, Dini G, Rocha V, Passweg J, Sureda A, Tichelli A, Niederwieser D; for the European Group for Blood and Marrow Transplantation and the European Leukemia Net. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. *Cancer*. 2009 115:4715-26
- 5.1.238 Hidalgo-Curtis C, Apperley JF, Stark A, Jeng M, Gotlib J, Chase A, Cross NCP, Grand FH. Fusion of the *PDGFRB* to two distinct loci at 3p21 and a third at 12q13 in imatinib responsive myeloproliferative neoplasms. *Brit J Haem*. 2010 148:268-73.
- 5.1.239 Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley JF, Cervantes F, Deininger M, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman JM, Hehlmann R. Chronic myeloid leukemia. An update of concepts and management recommendations of European LeukemiaNet. *J Clin Oncol*. 2009 27:6041-51.
- 5.1.240 Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Müller MC, Hochhaus A, Cortes J, Chuah C, Dufva IH, Apperley JF, Yagasaki F, Pearson JD, Peter S, Rodriguez CS, Preudhomme C, Giles F, Goldman JM, Zhou W. Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation. *Blood*. 2009 114:5271-8.
- 5.1.241 Milojkovic D, Nicholson E, Apperley J, Holyoake T, Shepherd P, Drummond M, Szydlo R, Bua M, Foroni L, Reid A, Khorashad J, de Lavallade H, Rezvani K, Paliompeis C, Goldman J, Marin D. Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia. *Haematologica* 2009 95:224-31
- 5.1.242 Dickinson AM, Pearce KF, Norde n J, O'Brien SG, Holle r E, Bickeböller H, Balavarc aY, Rocha V, Kolb HJ, Hromadnikova I, Sedlacek P, Niederwieser D, Brand R, Ruutu T, Apperley J, Szydlo R, Goulmy E, Siegert W, de Witt e T, Gratwohl A. 2009 Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. *Haematologica* 95, 922-927
- 5.1.243 Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Rogers J, Gallo J, Foss F, Apperley JF, Zhang MJ, Horowitz MM, Abhyankar S. Extracorporeal Photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2009 45:1068-76
- 5.1.244 Shaw BE, Mayor NP, Russell NH, Apperley JF, Clark RE, Cornish J, Darbyshire P, Ethell ME, Goldman JM, Little AM, Mackinnon S, Marks DI, Pagliuca A, Thomson K, Marsh SG, Madrigal JA. Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. *Leukemia*. 2009 24:58-65
- 5.1.245 de Lavallade H, Finetti P, Carbuccia N, Khorashad JS, Charbonnier A, Foroni L, Apperley JF, Vey N, Bertucci F, Birnbaum D, Mozziconacci MJ. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. *Leuk Res*. 2009 34:254-7.
- 5.1.246 Vianello F, Tisato V, Villanova F, Lymperi S, Ho KK, Gomes AR, Marin D, Bonnet D, Apperley JF, Lam EWF, Dazzi F. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukaemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. *Hematologica* 2010 95:1081-9.
- 5.1.247 Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J, McQuaker G, Marks DI, Craddock C, McCann S, Russell N, Cook G, Kottaridis PD. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. *Bone Marrow Transplant*. 2010 Feb 45:1587-93
- 5.1.248 Cordonnier C, Labopin M, Chesnel V, Ribaud P, Camara RD, Martino R, Ullmann AJ, Parkkali T, Locasciulli A, Yakouben K, Pauksens K, Bonnet E, Einsele H, Niederwieser D, Apperley J, Ljungman P. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWP01 trial. *Vaccine*. 2010 28:2730-4
- 5.1.249 Pavlu J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, Macdonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. *Blood*. 2010 115:4018-20

- 5.1.250 Frewer LJ, Coles D, de Lans I, Schroeder D, Champion K, Apperley JF. Impact of the European Clinical Trials Directive on prospective academic clinical trials associated with blood and marrow transplantation. *Bone Marrow Transplant* 2010 46:443-7
- 5.1.251 Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. *J Clin Oncol* 2010 28:2381-8
- 5.1.252 Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Feroni L, Khorashad JS. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. *Leukemia* 2010 24:1243-5
- 5.1.253 Sobrinho-Simões MA, Wilczek V, Score J, Cross NCP, Apperley JF, Melo JV. In search of the original leukaemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. *Blood* 2010 116:1329-35
- 5.1.254 Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D, Björkstrand B, Gahrton G, European Group for Blood and Marrow Transplantation and the European Leukemia Net. Primary plasma cell leukemia and autologous stem cell transplantation. *Haematologica* 2010 95: 804-809
- 5.1.255 Auner HW, Mazzarella L, Cook L, Szydlo R, Saltarelli F, Pavlu J, Bua M, Giles C, Apperley JF, Rahemtulla A. High rate of stem cell mobilisation failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. *Bone Marrow Transplant* 2010 46: 364-7
- 5.1.256 Gabriel IH, Sergeant R, Szydlo R, Apperley JF, de Lavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, et al. Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival following autologous stem cell transplantation in patients with multiple myeloma. *Blood* 2010 116:2033-9.
- 5.1.257 Pavlů J, Auner HW, Ellis S, Szydlo RM, Giles C, Contento A, Rahemtulla A, Apperley JF, Naresh K, Macdonald DH, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. *Hematol Oncol* 2011 29:75-80
- 5.1.258 Loren AW, Chow E, Jacobson DA, Gilleece M, Halter J, Joshi S, Wang Z, Gupta V, Hale GA, Marks DI, Stadtmauer EA, Apperley J, Cahn JY, Schouten HC, Lazarus HM, Savani B, McCarthy PL, Jakubowski AA, Kamani NR, Hayes-Lattin B, Maziarz RT, Warwick AB, Sorror ML, Bolwell BJ, Socié G, Wingard JR, Rizzo JD, Majhail NS. Pregnancy after hematopoietic-cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). *Biol Blood Marrow Transplant.* 2010 17:157-66
- 5.1.259 Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, Brett S, Stringaris K, Loucaides E, Howe K, Marin D, Kanfer E, Cooper N, Macdonald D, Rahemtulla A, Atkins M, Danga A, Milojkovic D, Gabriel I, Khoder A, Alsuliman A, Apperley J, Rezvani K. Humoral and cellular immunity to primary H1N1 infection in patients with hematological malignancies and following stem cell transplantation. *Biol Blood Marrow Transplant.* 2010 17:632-9
- 5.1.260 Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J, Bua M, Reid A, Feroni L, Rezvani K, Goldman J, Marin D. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. *Blood.* 2010 116:1014-6.
- 5.1.261 Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, Feroni L, Reid A, de Lavallade H, Rezvani K, Dazzi F, Apperley JF, Goldman JM, Marin D. Efficacy of tyrosine kinase inhibitors (TKI) as third line therapy in patients with chronic myeloid leukemia in chronic phase who have failed two prior TKI. *Blood.* 2010 116:5497-500
- 5.1.262 Szydlo RM, Gabriel I, Olavarria E, Apperley J. Sign of the Zodiac as a predictor of survival for recipients of an allogeneic stem cell transplant for chronic myeloid leukaemia (CML): an artificial association. *Transplant Proc.* 2010 42:3312-5

- 5.1.263 Schwarb H, May P, Apperley JF, Naresh KN. Bone marrow trephine biopsy findings in B acute lymphoblastic leukaemia of early precursor (Pro-B) subtype. *American Journal of Hematology* 2010 86:195-6.
- 5.1.264 Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, Goldschmidt H, Jouet JP, Harousseau JL, Morgan G, De Witte T, Neiderwieser D, Gahrton G. Efficacy and outcome of autologous transplantation in rare myelomas. *Haematologica*. 2010 95:2126-33
- 5.1.265 Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Bene' MC, Berger U, Buchner T, Burnett A, Cross N, De Witte T, Dohner H, Dombret H, Einsele H, Engelich G, Foa' R, Fonatsch C, Goekbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjan JJ, Labar B, Ljungman P, Mansman U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Sausele S. The European Leukemia Net: achievements and perspectives. *Haematologica*. 2010 96:156-62.
- 5.1.266 Daghistani M, Marin D, Sorouri Khorashad J, Wang L, May PC, Paliompeis C, Milojkovic D, De Melo VA, Gerrard G, Goldman JM, Apperley JF, Clark RE, Foroni L, Reid AG EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. *Blood*. 2010 116:6014-7
- 5.1.267 de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani K. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. *Haematologica* 2011;96 307-314
- 5.1.268 Shaw BE, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL. Unrelated donor peripheral blood stem cell transplants incorporating pretransplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic GVHD. *Br J Haematol*. 2011 153:244-52.
- 5.1.269 Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, de Witte T, Ljungman P, McDonald F, McGrath E, Passweg J, Peters C, Rocha V, Slaper-Cortenbach I, Sureda A, Tichelli A, Apperley JF. Introduction of a quality management system and outcome after hematopoietic stem cell transplantation. *J Clin Oncol*. 2011 29:1980-6. Epub 2011 Apr 11.
- 5.1.270 Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. *Blood*. 2011 117:3733-36 [Epub ahead of print].
- 5.1.271 Gerrard G, Mudge K, Stewart R, Foskett P, Stevens D, Khorashad JS, Szydlo R, Rezvani K, Marin D, Reid A, Apperley J, Goldman J, Foroni L. Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies. *Am J Hematol*. 2011 86:313-5. Epub 2011 Feb 15.
- 5.1.272 Babb A, Farah N, Lyons C, Lindsay K, Reddy N, Goldman J, Apperley JF, Salooja N. Uptake and outcome of assisted reproductive techniques in long-term survivors of SCT. *Bone Marrow Transplant*. 2012 47:568-73.
- 5.1.273 Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. *Leukemia*. 2012 26:296-302.
- 5.1.274 Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, Macdonald D, Dazzi F, Milojkovic D, Foroni L, Pavlu J, Sargent J, Le Dieu R, Goldman JM, Apperley J, Szydlo R. EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplant procedure. *Biol Blood Marrow Transplant*. 2012 18:235-40. Epub 2011 Jun 30
- 5.1.275 Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, Fielding AK, Pagliuca A, Mufti G, Raj K, Marks D, Amrolia P, Peniket A, Medd P, Potter MN, Shaw BE, Scarisbrick JJ. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous graft versus host disease. *Bone Marrow Transplant*. 2012 47:824-30. Epub 2011 Sep 19.

- 5.1.276 Ibrahim AR, Clark RE, Holyoake TL, Byrne J, Shepherd P, Apperley JF, Milojkovic D, Szydlo RM, Goldman JM, Marin D. Second generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia who have failed imatinib therapy. *Haematologica*. 2011 96:1779-82. Epub 2011 Aug 22.
- 5.1.277 Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussière H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. *Blood*. 2011 118:5697-700. Epub 2011 Sep 16.
- 5.1.278 Malard F, Kröger N, Gabriel IH, Hübel K, Apperley JF, Basak GW, Douglas KW, Gheraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli RM, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. *Biol Blood Marrow Transplant*. 2012 18:314-7. Epub 2011 Oct 13.
- 5.1.279 Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Gheraldes C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli RM, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients: a subgroup analysis of the European Consortium of Stem Cell Mobilization. *Bone Marrow Transplant*. 2012 47: 1046-50. Epub 2011 Nov 14.
- 5.1.280 Le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. *Leukemia*. 2012 26:1189-94. Epub 2011 Nov 11.
- 5.1.281 Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L. BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation. *Am J Hematol*. 2012 87:298-304. Epub 2012 Jan 9.
- 5.1.282 Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, Reid A, Rezvani K, Foroni L, Goldman J, Marin D. Responses to second line tyrosine kinase inhibitors are durable: an intention to treat analysis in chronic myeloid leukemia patients. *Blood*. 2012 119:1838-43 Epub 2011 Dec14.
- 5.1.283 Milojkovic D, Ibrahim A, Reid A, Foroni L, Apperley J, Marin D. Efficacy of combining dasatinib and intensive chemotherapy for patients with chronic myeloid leukemia in blastic transformation. *Haematologica*. 2012 97:473-4. Epub 2011 Dec 1.
- 5.1.284 Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla A. Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. *Br J Haematol*. 2012 157:125-7. Epub 2011 Nov 3.
- 5.1.285 Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L. Assessment of BCR-ABL1 Transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. *J Clin Oncol*. 2012 30:232-8. Epub 2011 Nov 7.
- 5.1.286 Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, Macdonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. *Blood*. 2012 119:5030-6. Epub 2012 Feb 27.
- 5.1.287 Basak GW, Wiktor-Jedrzejczak W, Apperley JF, Douglas KW, Gabriel IH, Gheraldes C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. *Bone Marrow Transplant*. 2012 47:1003-5. Epub 2011 Oct 10



- 5.1.288 Gerrard G, Mudge K, Foskett P, Stevens D, Alikian M, White HE, Cross NC, Apperley J, Foroni L. Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization. *Am J Hematol.* 2012 87:717-20. Epub 2012 May 6
- 5.1.289 Marin D, Hedgley C, Clark RE, Apperley JF, Foroni L, Milojkovic D, Pocock C, Goldman JM, O'Brien S. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. *Blood.* 2012 120:291-4. Epub 2012 May 29.
- 5.1.290 Worel N, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Gerald C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Duarte RF, Mohty M. European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. *Transfusion* 2012 52:2395-400. Epub 2012 Mar 13
- 5.1.293 Neave EL, Schwarb H, Shlebak A, Layton DM, Apperley JF, Pavlu J. Lymphodepletion chemotherapy followed by donor leukocytes for post transplantation relapse of myelofibrosis after previous donor leukocyte infusion failure. *European Journal of Hematology* 2013 90:76-8. Epub 2012 Nov 29
- 5.1.294 Auner HW, Szydlo R, Rone A, Chaidos A, Giles C, Kanfer E, Macdonald DH, Marin D, Milojkovic D, Pavlu J, Apperley JF, Rahemtulla A. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. *Leuk Lymphoma.* 54:2200-2204 Epub 2013 Feb 7
- 5.1.295 Loren AW, Brazauskas R, Chow EJ, Gilleece M, Halter J, Jacobsohn DA, Joshi S, Pidala J, Quinn GP, Wang Z, Apperley JF, Burns LJ, Hale GA, Hayes-Lattin BM, Kamble R, Lazarus H, McCarthy PL, Reddy V, Warwick AB, Bolwell BJ, Duncan C, Socie G, Sorror ML, Wingard JR, Majhail NS. Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients. *Bone Marrow Transplantation* Epub 2013 Feb 18
- 5.1.296 Innes AI, Beattie R, Sergeant R, Ghandi D, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, MacDonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman JM, Apperley JF, Szydlo R, Dazzi F, Rezvani K. Escalating-dose HLA-mismatched donor lymphocyte infusion is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allogeneic stem cell transplantation. *Bone Marrow Transplant* 2013 48:1324-8 Epub May 20
- 5.1.297 Patel A, Waheed U, Brett SJ, Rahemtulla A, Apperley J, Patel P. Rapid initial response of myeloma hyperammonemic encephalopathy to L-ornithine-L-aspartate (LOLA) and dexamethasone therapy *Leukemia & Lymphoma* 2013 Epub May 15
- 5.1.298 Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Müller MC, Hochhaus A, Dufva IH, Kim D-W, Cortes J, Mauro MJ, Chuah C, Labussière H, Morisset S, Roche-Lestienne C, Lippert E, Hayette S, Peter S, Zhou W, Maguer-Satta V, Michallet M, Goldman J, Apperley JF, Mahon FX, Marin D, Etienne G. The BCR-ABL<sub>1315</sub> mutation compromises survival in chronic phase CML patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. *Haematologica* 2013 98:1510-6 Epub May 28
- 5.1.299 De Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, Milojkovic D, Foroni L, Chaidos A, Cooper N, Gabriel I, Apperley J, Belsey S, Flanagan RJ, Goldman J, Shpall EJ, Kelleher P, Marin D, Rezvani K. Tyrosine kinase inhibitors impair B cell immune responses in CML through off-target inhibition of kinases important for cell signaling. *Blood* 2013 122:227-38. Epub 2013 May 29
- 5.1.300 Loaiza S, Haynes R, Bray E, Finn SA, Rezvani K, Apperley JF, Davis J. Donor lymphocyte collections using the spectra Optia MNC version 5. *Transfusion and Apheresis Science* 2013, 48: 171. Epub 2013 Mar 13.
- 5.1.301 Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saúbele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia *Blood.* 2013 122:872-84. Epub Jun 26.
- 5.1.302 Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D. Prophylaxis and treatment of

GVHD: EBMT-ELN working group recommendations for a standardized practice [Special Report]. *Bone Marrow Transplantation* 2014 49:319, 2013 Epub Jul 29.

- 5.1.303 Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H for the PACE Investigators. Ponatinib in Refractory Philadelphia Chromosome Positive Leukemias: The PACE Trial. *New England Journal of Medicine* 2013 369:1783-96 [Epub ahead of print].
- 5.1.304 Gerull S, Stern M, Apperley J, Beelen D, Brinch L, Bunjes D, Butler A, Ganser A, Ghavamzadeh A, Koh MB, Komarnicki M, Kröger N, Maertens J, Maschan A, Peters C, Rovira M, Sengeløv H, Socie G, Tischer J, Oneto R, Passweg J, Marsh J. Syngeneic transplantation in aplastic anemia: pretransplant conditioning and peripheral blood are associated with improved engraftment - an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2013 98:1804-9. Epub 2013 Jul 26.
- 5.1.305 Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. *Blood*. 2013 122:1923-34 Epub 2013 Aug 7. Erratum in: *Blood*. 2014 123:3056.
- 5.1.306 Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. *J Clin Invest*. 2013 123:4144-57. Epub 2013 Sep 3.
- 5.1.307 Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. *Blood*. 2013 122:3034-44. Epub 2013 Aug 22
- 5.1.308 Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, Valgañon M, Nteliopoulos G, White D, Marin D, Hedgley C, O'Brien S, Clark R, Goldman JM, Milojkovic D, Apperley JF, Feroni L. A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. *Br J Haematol*. 2013 163:631-9. Epub 2013 Oct 10.
- 5.1.309 Pearce KF, Hildebrandt M, Greinix H, Scheduling S, Koehl U, Worel N, Apperley J, Edinger M, Hauser A, Mischak-Weissinger E, Dickinson AM, Lowdell MW. Regulation of advanced therapy medicinal products in Europe and the role of academia. *Cytotherapy* 2014 16:289-297 Epub ahead of print Oct 12 2013
- 5.1.310 Auner HW, Moody AM, Ward TH, Kraus M, Milan E, May P, Chaidos A, Driessen C, Cenci S, Dazzi F, Rahemtulla A, Apperley JF, Karadimitris A, Dillon N. Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells. *PLoS One*. 2013 Sep 17;8(9):e74415.
- 5.1.311 Dignan F, Aguilar-Duran S, Scarisbrick J, Shaw B, Potter M, Cavenagh J, Apperley JF, Fielding A, Pagliuca A. Impact of Extracorporeal Photopheresis on Skin scores and Quality of Life in Patients with Steroid-refractory Chronic Graft-versus-Host Disease. *BMT* 2014 49:704-8. Epub 2014 Feb 24
- 5.1.312 Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P, Baldomero H, Chabannon C, Apperley J. Use of the quality management system 'JACIE' and outcome after hematopoietic stem cell transplantation. *Haematologica*. 2014 99:908-15. Epub 2014 Jan 31.
- 5.1.313 Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, Marin D, Mielke S, Apperley JF, Shpall EJ, Barrett AJ, Rezvani K. Leukemia-induced phenotypic

and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. *Haematologica*. 2014 99:836-47

5.1.314 Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long term remissions with imatinib. *Blood*. 2014 123:3574-7

5.1.315 Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Gheraldes C, Jaksic O, Kattan MW, Koristek Z, Lanza F, Lemoli RM, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten HC, Selleslag D, Suci S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte RF. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2014 49:865-72. Epub 2014 Mar 31.

5.1.316 Morris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff GW, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kroger N, de Witte T, Ruutu T; Chronic Malignancies and Lymphoma Working Parties of the EBMT. Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. *Transfusion*. 2014 54:2514-22. Epub 2014 Jun 26.

5.1.317 Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria E. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. *Haematologica*. 2014 99:1492-8. Epub 2014 Jul 4.

5.1.318 Alonso-Dominguez JM, Grinfeld J, Alikian M, Marin D, Reid A, Daghistani M, Hedgley C, O'Brien S, Clark RE, Apperley J, Foroni L, Gerrard G. PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. *Am J Hematol*. 2015 90:20-6. Epub 2014 Oct 18

5.1.319 Palani R, Apperley JF, Reid A, Foroni L, Deplano S, Milojkovic D. Thyroid function abnormalities associated with ponatinib therapy in patients with chronic myeloid leukaemia. *Thyroid*. 2015 Mar 17. [Epub ahead of print]

5.1.320 Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. *Am J Hematol* 2015 2015 90:1111-5.

5.1.321 Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, Ljungman P, McGrath E, Mohty M, Nagler A, Rambaldi A, Ruiz de Elvira C, Snowden J, Passweg J, Apperley JF, Niederwieser D, Stijnen T, Brand R, for the Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy (ISCT) and the European Group for Blood and Marrow Transplantation (EBMT) and the European Leukemia Net (ELN). Macroeconomics and outcome after hematopoietic stem cell transplantation. *EBiomedicine* 2015 19;2:2101-9.

5.1.322 Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SGE, Madrigal A, Vardhman K, Peggs KS, Beck S. A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation. *Genome Medicine*. 2015 15;7:128

5.1.323 Lishner M, Avivi I, Apperley JF, Evens AM, Fumagalli M, Nulman I, Oduncu FS, Peccatori FA, Robinson S, Van Calsteren K, Vandenbroucke T, Van den Heuvel F, Amant F. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. *J Clin Oncol*. 2016 Feb 10;34(5):501-8

5.1.324 Arrieta-Bolaños E, Mayor NP, Marsh SG, Madrigal JA, Apperley JF, Kirkland K, Mackinnon S, Marks DI, McQuaker G, Perry J, Potter MN, Russell NH, Thomson K, Shaw BE. Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors. *Haematologica*. 2016 Mar;101(3):382-90

- 5.1.325 Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, Breuer CK, Caulfield T, Cedars MI, Frey-Vasconcells J, Heslop HE, Jin Y, Lee RT, McCabe C, Munsie M, Murry CE, Piantadosi S, Rao M, Rooke HM, Sipp D, Studer L, Sugarman J, Takahashi M, Zimmerman M, Kimmelman J. Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. *Stem Cell Reports* 2016 6:787-97 01 Jan 2016 [Epub ahead of print].
- 5.1.326 Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States *J Natl Cancer Inst.* 2016 Mar 4;108
- 5.1.327 Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, Arnold R, Bron D, Cordonnier C, Ernst P, Ferrant A, Frassoni F, Gahrton G, Richard C, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schattenberg A, Schmitz N, Torres-Gomez A, Zwaan F, Apperley J, Olavarria E, Kröger N; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation EBMT. Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. *Ann Hematol.* 2016 95:967-72
- 5.1.328 Gerrard G, Foong HE, Mudge K, Alikian M, Apperley JF, Foroni L. Cepheid Xpert Monitor Platform for the Confirmation of BCR-ABL1 IS Conversion Factors for the Molecular Monitoring of Chronic Myeloid Leukaemia. *Leukemia Research Leuk Res.* 2016;49:47-50.
- 5.1.329 Claudiani S, Apperley JF, Deplano S, Khorashad J, Foroni L, Palanicawander R, Perry R, Milojkovic D. Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia. *American Journal of Hematology* 2016 91:E480-E481
- 5.1.330 Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, Simões BP, Ferster A, Dupont S, de la Fuente J, Dalle JH, Zecca M, Walters MC, Krishnamurti L, Bhatia M, Leung K, Yanik G, Kurtzberg J, Dhedin N, Kuentz M, Michel G, Apperley J, Lutz P, Neven B, Bertrand Y, Vannier JP, Ayas M, Cavazzana M, Matthes-Martin S, Rocha V, Elayoubi H, Kenzey C, Bader P, Locatelli F, Ruggeri A, Eapen M. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. *Blood.* 2016 129:1548-1556.
- 5.1.331 Alikian M, Whale AS, Akiki S, Piechocki K, Torrado C, Myint T, Cowen S, Griffiths M, Reid AG, Apperley J, White H, Huggett JF, Foroni L. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia. *Clin Chem.* 2016 63:525-531
- 5.1.332 Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, Tsai PC, Ried JS, Zhang W, Yang Y, Tan S, Fiorito G, Franke L, Guarrera S, Kasela S, Kriebel J, Richmond RC, Adamo M, Afzal U, Ala-Korpela M, Albeti B, Ammerpohl O, Apperley JF, Beekman M, Bertazzi PA, Black SL, Blancher C, Bonder MJ, Brosch M, Carstensen-Kirberg M, de Craen AJ, de Lusignan S, Dehghan A, Elkalaawy M, Fischer K, Franco OH, Gaunt TR, Hampe J, Hashemi M, Isaacs A, Jenkinson A, Jha S, Kato N, Krogh V, Laffan M, Meisinger C, Meitinger T, Mok ZY, Motta V, Ng HK, Nikolakopoulou Z, Nteliopoulos G, Panico S, Pervjakova N, Prokisch H, Rathmann W, Roden M, Rota F, Rozario MA, Sandling JK, Schafmayer C, Schramm K, Siebert R, Slagboom PE, Soininen P, Stolk L, Strauch K, Tai ES, Tarantini L, Thorand B, Tigchelaar EF, Tumino R, Uitterlinden AG, van Duijn C, van Meurs JB, Vineis P, Wickremasinghe AR, Wijmenga C, Yang TP, Yuan W, Zhernakova A, Batterham RL, Smith GD, Deloukas P, Heijmans BT, Herder C, Hofman A, Lindgren CM, Milani L, van der Harst P, Peters A, Illig T, Relton CL, Waldenberger M, Jarvelin MR, Bollati V, Soong R, Spector TD, Scott J, McCarthy MI, Elliott P, Bell JT, Matullo G, Gieger C, Kooner JS, Grallert H, Chambers JC. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. *Nature.* 2017 541:81-86.
- 5.1.333 Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N. Lineage-specific genes are prominent DNA damage hotspots during leukemic transformation of B-cell precursors. *Cell Reports* January 2017 18:1687-1698
- 5.1.334 Pello OM, Innes AJ, Bradshaw A, Finn SA, Uddin S, Bray E, Olavarria E, Apperley JF, Pavlů J. Pello OM, Innes AJ, Bradshaw A, Finn SA, Uddin S, Bray E, Olavarria E, Apperley JF, Pavlů J. BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. *Eur J Haematol.* 2017 98:632-634

- 5.1.335 Tamaddon M, Burrows M, Ferreira SA, Dazzi F, Apperley JF, Bradshaw A, Brand DD, Czernuszka J, Gentleman E. Monomeric, porous type II collagen scaffolds promote chondrogenic differentiation of human bone marrow mesenchymal stem cells in vitro. *Sci Rep.* 2017 7:43519
- 5.1.336 Gratwohl A, Sureda A, Cornelissen J, Apperley J, Dreger P, Duarte R, Greinix HT, Mc Grath E, Kroeger N, Lanza F, Nagler A, Snowden JA, Niederwieser D, Brand R. Alloreactivity: The janus-face of hematopoietic stem cell transplantation. *Leukemia.* 2017 31(8):1752-1759
- 5.1.337 Alikian M, Gale RP, Apperley JF, Foroni L. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia, *Biomol Detect Quantif.* 2017 Feb 14;11:4-20
- 5.1.338 Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. *Cancer.* 2017 123:2875-2880
- 5.1.339 Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne J, de Lavallade H, O'Brien S, Coffey T, Foroni L, Copland M. A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study. *Lancet Haematology* 2017 4:e310-e316
- 5.1.340 Pavlů J, Auner HW, Szydło RM, Sevillano B, Palani R, O'Boyle F, Chaidos A, Jakob C, Kanfer E, MacDonald D, Milojkovic D, Rahemtulla A, Bradshaw A, Olavarria E, Apperley JF, Pello OM. Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation. *Bone Marrow Transplant* 2017 52:1599-1601
- 5.1.341 Hashmi SK, Srivastava A, Rasheed W, Adil S, Wu T, Jagasia M, Nassar A, Hwang WYK, Hamidieh AA, Greinix HT, Pasquini MC, Apperley JF, Aljurf M. Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. *Hematol Oncol Stem Cell Ther.* 2017 10:167-172
- 5.1.342 Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, von Bonin M, Barbieri L, Halai K, Ward S, Weng L, Chakraverty R, Lombardi G, Watt FM, Orchard K, Marks DI, Apperley J, Bornhauser M, Walczak H, Bennett C, Dazzi F. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. *Sci Transl Med.* 2017 Nov 15;9(416).
- 5.1.343 Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne P, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N. Melphalan 140mg/m<sup>2</sup> or 200mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. *Haematologica.* 2018 Mar;103(3):514-521
- 5.1.344 Sahebi F, Iacobelli S, Sbianchi G2, Koster L, Blaise D, Reményi P, Russell NH, Ljungman P, Kobbe G, Apperley J, Trneny M, Mayer J, Wiktor-Jedrzejczak W, Sanchez JF, Schaap M, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson KMO, Yakoub-Agha I, González Muñoz S, Schönland S, Morris C, Garderet L, Kröger N. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. *Biology of Blood and Marrow Transplantation* 2018 24:930-936
- 5.1.345 Khoder A, Alsuliman A, Basar R, Sobieski C, Kondo K, Szydło R, Alousi AM, Muftuoglu M, Shaim H, Apperley JF, Gokdemir E, Cooper N, Mehta RS, Marin D, Champlin R, Shpall E, Rezvan K. Evidence for B cell exhaustion in chronic GVHD. *Frontiers in Immunology* 2018 8:1937
- 5.1.346 Xin X, Ding Y, Yang Y, Fu X, Zhou J, McKee C, Muschel R, Gale RP, Apperley JF, Xu D. Protease nexin-1 prevents growth of human B-cell lymphoma via inhibition of sonic hedgehog-signalling. *Blood Cancer J.* 2018 8:24
- 5.1.347 Czyz A, Labopin M, Giebel S, Socié G, Apperley J, Volin L, Reményi P, Yakoub-Agha I, Orchard K, Michallet M, Stuhler G, Chaganti S, Murray M, Aljurf M, Bloor A, Passweg J, Finke J, Mohty M, Nagler A. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult

patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. *Am J Hematol.* 2018 ;93:778-785

5.1.348 Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. *Blood.* 2018 132:393-404

5.1.349 Beckerson J, Szydlo RM, Hickson M, Mactier CE, Innes AJ, Gabriel IH, Palanicawandar R, Kanfer EJ, Macdonald DH, Milojkovic D, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlu J. Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. *Clin Nutr.* 2019 38:738-744

5.1.350 Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Intronà M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F. Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2018 24:2365-2370

5.1.351 Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. *Blood Cancer J.* 2018 8:88

5.1.352 Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarek RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma *Br J Haematol.* 2019 185:588-592

5.1.353 Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. *J Hematol Oncol.* 2018 11:143

5.1.354 Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E, Tholouli E, Saif M, Sivaprakasam P, Lawson S, Bloor A, Pagliuca A, Potter V, Mehra V, Snowden JA, Vora A, Kishore B, Hunter H, Apperley JF, Dazzi F. Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. *Br J Haematol.* 2019 185: 89-92.

5.1.355 Claudiani S, Gatenby A, Szydlo R, Nesr G, Abulafia AS, Palanicawandar R, Nteliopoulos G, Khorashad JS, Foroni L, Apperley JF, Milojkovic D. MR4 Sustained for 12 months is associated with Stable Deep Molecular Responses in Chronic Myeloid Leukemia. *Hematologica* 2019 104:(2206-2214

5.1.356 Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors. *Hematologica* 2019 104:2400-2409

5.1.357 Xu D, Claudiani S, Naresh K, Mucklow S, Neelakantan P, Yebra E, Apperley JF, Khorashad JS, Milojkovic D. Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1. *Leukemia and Lymphoma* 2019 60:3090-3091

5.1.358 Branford S, Kim D, Apperley J, Eide C, Mustjoki S, Tiong Ong S, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro M, Druker B, Kim DW, Mahon FX, Cortes J, Radich J, Hochhaus A, Hughes T. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. *Leukemia* 2019 33:1835-1850

5.1.359 Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M. Initial reduction of therapy prior to complete

treatment discontinuation in chronic myeloid leukaemia: Final results of the British DESTINY Study. *Lancet Hematology* 2019 6:e375-e383.

5.1.360 Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarek RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Preclinical toxicology and safety pharmacology of the first-in-class GADD45 $\beta$ /MKK7 inhibitor and clinical candidate, DTP3. *Toxicol Rep.* 2019 6:369-379

5.1.361 Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale G, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. *Biol Blood Marrow Transplant.* 2019 May 6 [Epub ahead of print].

5.1.362 Innes A, Woolley P, Szydlo R, Lozano S, Fernando F, Bansal D, Palanicawandar R, Milojkovic D, May P, Nadal-Melsio E, Yebra-Fernandez E, Olavarria E, Apperley JF, Pavlu J. Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. *Leukemia* 2019 Jul 15 [Epub ahead of print].

5.1.363 Gratwohl A, Duarte R, Snowden JA, van Biezen A, Baldomero H, Apperley JF, Cornelissen J, Greinix HT, McGrath E, Mohty M, Kroeger N, Nagler A, Niederwieser, Putter H, Brand R for the Joint Accreditation Committee (JACIE). Pre-transplantation risks and transplant techniques in hematopoietic stem cell transplantation for acute leukemia. *EClinical Medicine* *EClinicalMedicine.* 2019 15:33-41.

5.1.364 Petersdorf EW, Carrington M, O'hUigin C, Bengtsson M, De Santis D, Dubois V, Gooley T, Horowitz M, Hsu K, Madrigal JA, Maiers MJ, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Stevenson P; International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. *Lancet Haematol.* 2020 7:e50-e60

5.1.365 Brissot E, Labopin M, Russo D, Martin S, Schmid C, Glass B, Ram R, Ozkurt Z, Passweg J, Veelken H, Bunjes D, Apperley J, Giebel S, Mohty M, Nagler A. Alternative donors provide comparable results to matched-unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party 2020 55:1763-1772.

5.1.366 Hochhaus A, Bacarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sauße S, Soverini S, Steegmann JL, Turkina A, Zaritsky A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia.* 2020 34:966-984

5.1.367 Anthias C, Apperley J, Bloor A, Byrne J, Collin M, Crawley C, Craddock C, Finnegan D, Gilleece M, Gribben J, Hunter A, Hunter H, Koh M, Mackinnon S, Malladi R, Marks D, McQuaker G, Nikolousis M, Orchard K, Pavlu J, Peniket A, Potter M, Potter V, Robinson S, Russell N, Salim R, Snowden J, Thomson K, Tholouli E, Wilson K. Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. *Bone Marrow Transplant.* 2020 55:1840-1843

5.1.368 Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, Apperley J. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. *Leukemia.* 2020 34:1495-1502.

5.1.369 Hastings A, Apperley JF, Nadal-Mesio E, Brown L, Bain BJ. Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13). *American Journal of Hematology* 96:163-164

5.1.370 Chowdhury A, Loaiza S, Yebra-Fernandez E, Nadal-Melsio E, Apperley JF, Khorashad JS. An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets. *Br J Haematol.* 2020 190:e236-e239

- 5.1.371 Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, Goringe A, Rao A, Khorashad J, de Lavallade H, Mead AJ, Osborne W, Plummer C, Jones G, Copland M; A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. *Br J Haematol*. 2020 191:171-193]
- 5.1.372 Ostasov P, Robertson H, Piazza P, Datta A, Apperley JF, Houdová L, Lysák D, Holubová M, Caputo VS, Barozzi I. Evolution of advanced chronic lymphoid leukemia unveiled by single-cell transcriptomics: a case report. *Frontiers in Oncology*, 2020 October 30. 10:584607
- 5.1.373 Silvestri G, Trotta R, Stramucci L, Ellis JJ, Harb JG, Neviani P, Wang S, Eisfeld AK, Walker CJ, Zhang B, Srutova K, Gambacorti-Passerini C, Pineda G, Jamieson CHM, Stagno F, Vigneri P, Nteliopoulos G, May PC, Reid AG, Garzon R, Roy DC, Moutouou MM, Guimond M, Hokland P, Deininger MW, Fitzgerald G, Harman C, Dazzi F, Milojkovic D, Apperley JF, Marcucci G, Qi J, Polakova KM, Zou Y, Fan X, Baer MR, Calabretta B, Perrotti D. Persistence of drug-resistant leukemic stem cells and impaired NK cell immunity in CML patients depend on MIR300 antiproliferative and PP2A-activating functions. *Blood Cancer Discov*. 2020 1:48-67.
- 5.1.374 Mason CC, Fiol CR, Baker MJ, Nadal-Melsio E, Yebra-Fernandez E, Bicalho L, Chowdhury A, Albert M, Reid AG, Claudiani S, Apperley JF, Khorashad JS. Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy. *Br J Haematol* 2020 192:137-145.
- 5.1.375 Abruzzese E, Apperley JF, Mauro MJ, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations, *Ther Adv Hematol* 2020, 11:1–13,
- 5.1.376 Claudiani S, Apperley JF, Szydlo R, Khan A, Nesr G, Hayden C, J Innes A, Dominy K, Foskett P, Foroni L, Khorashad J, Milojkovic D. TKI dose reduction can effectively maintain major molecular remissions in patients with chronic myeloid leukaemia. *Brit J Haem* 2021 93:346-355
- 5.1.377 Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. *Blood Advances* 2021 5:1102-110
- 5.1.378 Garderet L, Sbianchi G, Iacobelli S, Blaise D, Byrne JL, Remenyi P, Apperley JF, Touzeau C, Isaksson C, Browne P, Mayer J, Lenhoff S, Gonzalez Muniz S, Parody Porras R, Basak G, Poire X, Trneny M, Nagler A, Michieli M, Tanase A, Koster L, Hayden PJ, Beksac M, Schönland S, Yakoub-Agha I. Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: results from the CALM study by the CMWP of the EBMT. *Eur J Haematol* 2021 106:708-715
- 5.1.379 Eiring A, Bencomo-Alvarez A, Rubio A, Olivas I, Gonzalez M, Ellwood R, Ripoll Fiol C, Eide C, Lara J, Barreto-Vargas C, Jave-Suarez L, Nteliopoulos G, Reid A, Milojkovic D, Druker B, Apperley JF, Khorashad J. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. *Oncogene* 2021 40:2697-2710
- 5.1.380 Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Al Zahrani M, Martino Bofarull RM, Calbacho M, Ciceri F, Lopez-Corral L, Crippa C, Deconinck E, Fox ML, Grassi A, Jimenez MJ, Koçulu S, Kwon M, Vallejo Llamas C, López Lorenzo JL, Mielke S, Orchard K, Parody Porras R, Vallisa D, Xhaard A, Knelange NS, Cedillo A, Kröger N, Piñana JL, Styczynski J. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. *Leukemia* 2021 [Epub ahead of print]
- 5.1.381 Lawless S, Sbianchi G, Morris C, Iacobelli S, Bosman P, Blaise D, Reményi P, Byrne JL, Mayer J, Apperley J, Mielke S, Kobbe G, Schaap N, Isaksson C, Lenhoff S, Basak G, Chevallier P, Wilson KMO, Muñoz SG, Scheid C, Browne P, Anagnostopoulos A, Rambaldi A, Jantunen E, Kröger N, Schönland S, Yakoub-Agha I, Garderet L. IgD subtype but not IgM or NS (non secretory) is a prognostic maker for poor survival following autologous stem cell transplantation in multiple myeloma. Results from the EBMT CALM (Collaboration to collect Autologous transplant outcomes in Lymphomas and Myeloma) Study. *Lymphoma, Myeloma and Leukaemia* 2020 [Epub ahead of print].
- 5.1.382 Innes AJ, Mullish BH, Ghani R, Szydlo RM, Apperley JF, Olavarria E, Palanicawandar R, Kanfer E, Milojkovic D, McDonald JAK, Branngian ET, Thursz MR, Williams HRT, Davies FJ, Marchesi JR, Pavlů J. Fecal microbiota transplant mitigates adverse outcomes in patients colonized with multidrug-resistant organisms undergoing allogeneic hematopoietic cell transplantation. *Frontiers in Cellular and Infection Microbiology*, section Microbiome in Health and Disease 12 Aug 2021 [Epub ahead of print],



5.1.383 Cortes J, Apperley JF, Lomaia E, Moiraghi B, Undurraga MS, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA, McCloskey J, Hochhaus A, Rousselot P, Rosti G, de Lavallade H, Turkina A, Rojas C, Arthur C, Maness LJ, Talpaz M, Mauro MJ, Hall T, Lu V, Srivastava S, Deininger MW. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A Randomized, Open-Label Phase 2 Clinical Trial *Blood*. 2021 Aug 18, [Epub ahead of print]

5.1.384 Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina AG, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garcia-Gutierrez V, Cortes J, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after  $\geq 2$  prior TKIs. *Blood*. 2021 Aug 18, [Epub ahead of print]

5.1.385 Claudiani S, Mason CC, Milojkovic D, Bianchi A, Pellegrini C, Di Marco A, Fiol C, Robinson M, Ponnusamy K, Mokretar K, Chowdhury A, Albert M, Reid AG, Deininger MW, Naresh K, Apperley JF, Khorashad JS. Carfilzomib enhances the suppressive effect of ruxolitinib in myelofibrosis. *Cancers* 2021 13:4863.

5.1.386 Booth S, Curley HM, Varnai C, Arnold R, Lee LYW, Campton NA, Cook G, Purshouse K, Aires J, Innes A, Cook L, Tomkins O, Oram H, Tilby M, Kulasekararaj A, Wrench D, Dolly S, Newsom-Davies T, Pettengell R, Gault A, Moody S, Mittal S, Altohami M, Tillet T, Leonard P, Mukherjee L, Apperley JF, Ashcroft J, Rabin N, Carmichael J, Cazier JB, Kerr R, Middleton G, UKCCMP team, Collins GP, Palles C. Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. *British Journal of Haematology* 2021 [Epub ahead of print].

5.1.387 Dominy K, O'Hare M, Szydlo R, Claudiani S, Foskett P, Foroni L, Milojkovi Dc, Apperley JF, Khorashad JS. Assessment of quantitative PCR for BCR-ABL1 transcripts in CML: are improved outcomes in patients with e14a2 transcripts an artefact of technology? *British Journal of Haematology* 2021 [Epub ahead of print].

5.1.388 Buske C, Dreyling M, Alvarez-Larrán A, Apperley JF, Arcaini L, Besson C, Bullinger L, Corradini P, Della Porta MG, Dimopoulos M, D'Sa S, Eich HT, Foà R, Ghia P, Gomes da Silva M, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian JJ, Kröger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Managing hematological cancer patients during the COVID-19 pandemic: An ESMO-EHA Interdisciplinary Expert Consensus. *ESMO Open* 2021 [Epub ahead of print].

## 5.2 *Invited papers/Editorials/Annotations/Reviews/Books*

5.2.1 Apperley JF and Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia. *Plasma Therapy and Transfusion Technology* 1985 6: 207-220.

5.2.2 Goldman JM and Apperley JF. Bone marrow transplantation for chronic myeloid leukaemia. *Progress in Bone Marrow Transplantation* ed. Gale RP, Champlin R. New York, Alan Liss 1987: 97-102.

5.2.3 Apperley JF, Williams DA. Gene Therapy: current status and future directions. *British Journal of Haematology* 1990 75: 148-155.

5.2.4 Williams DA, Lim B, Apperley JF, Orkin D, Beier D, Cone R. Gene transfer into murine hematopoietic stem cells and bone marrow stromal cells. *Molecular Biology of Hematopoiesis*. 1990. NG Abraham, G Konwalinka, L Sachs, CJ Wiedermann (eds).

5.2.5 Apperley JF. The role of bone marrow transplantation and gene transfer in the haemoglobinopathies (chapter). *Balliere's Clinical Haematology* 1993 6:1 299-325.

5.2.6 Apperley JF. Gene therapy for haematological diseases. *British Journal of Biomedical Science* 1994 51: 81-85.

- 5.2.7 Apperley JF. Umbilical cord blood progenitor cell transplantation. *Bone Marrow Transplantation* 1994 14: 187-196.
- 5.2.8 Virchis AE, Apperley JF. Current clinical applications of detection of minimal residual disease. *Current Medical Literature: Leukaemia and Lymphoma* 1995 3:1 3-11.
- 5.2.9 Apperley JF, Reddy N. Mechanism and management of treatment related gonadal failure in recipients of high dose chemoradiotherapy. *Blood Reviews* 1995, 9: 93-116.
- 5.2.10 Apperley JF, Roberts IAG. The current status of bone marrow transplantation and gene therapy in the management of the haemoglobinopathies. In: Smit Sibinga CTh, Das PC and Briet E (eds) *Hereditary Diseases and Blood Transfusion*, Kluwer Academic Publishers, Dordrecht, 1995, pp71-80.
- 5.2.11 Gratwohl A, Gorin NC, Apperley JF, Goldstone A, Rosti G, Bacigalupo A, Gluckman E, Fischer A, Ljungman P, Kolb HJ, Niethammer D. The European Group for Blood and Marrow Transplantation (EBMT): a report from the President and the Chairmen of the Working Parties. *Bone Marrow Transplantation* 1996 18: 677-692.
- 5.2.12 Carella AM, Frassoni F, Melo J, Sawyers C, Eaves C, Eaves A, Apperley JF et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. *Haematologica* 1997, 82: 478-495.
- 5.2.13 Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. on behalf of the Myeloma Subcommittee of the EBMT Chronic Leukaemia Working Party and the Myeloma Working Committee of the IBMTR and the ABMTR. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. *British Journal of Haematology* 1998, 102: 1115-1123.
- 5.2.14 Apperley JF. Hematopoietic stem cell transplantation in chronic myeloid leukaemia. *Current Opinion in Hematology*. 1998 5: 445-453.
- 5.2.15 Apperley JF, Dazzi F, Craddock C, Goldman JM. Immunotherapy for chronic myeloid leukaemia. *Hematology and Cell Therapy*. 1998 40: 229-232.
- 5.2.16 Croucher PI, Apperley JF. Bone disease in multiple myeloma. *British Journal of Haematology* 1998 103: 902-1191.
- 5.2.17 Stocchi R, Ward K, Fanin R, Bacarani M, Apperley JF. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. *Haematologica* 1998 84: 71-79.
- 5.2.18 Apperley JF, Croucher PI. Bisphosphonates in multiple myeloma. *Pathologie Biologie* 1999, 47: 178-181.
- 5.2.19 Apperley JF, Gluckman E, Gratwohl, A. Eds. *The EBMT Handbook: Blood and Marrow Transplantation*. European School of Haematology & Robert Arts Graphiques, Paris 1998 (1st edition), 2000 (2nd edition).
- 5.2.20 Garin M, Apperley J, Dazzi F. Adoptive immunotherapy with allogeneic T cells: the use of a suicide gene to control graft-versus-host disease. In: *Cancer Immunotherapy Protocols*, Humana Press, 2000.
- 5.2.21 Apperley JF. Results with alternative donors, in Carella AM, Daley G, Eaves CJ, Goldman JM, Hehlmann R (Eds) *Chronic Myeloid Leukaemia: Biology and Treatment*. Martin Dunitz, London, 2001 pp 323-338
- 5.2.22 Terpos E, Apperley J, Samson DM, Rahemtulla A. Management of multiple myeloma. *Haema* 2002 5: 21-35.
- 5.2.23 Melo JM, Hughes TP. Apperley JF. Chronic myeloid leukemia. *Hematology (Am Soc Hematol Educ Program)*. 2003:132-52.
- 5.2.24 Radich JP, Olavarria E, Apperley JF. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. *Hematol Oncol Clin North Am* 2004 18:685-702.

- 5.2.25 Apperley JF. Just another cost increasing exercise (JACIE). *Bone Marrow Transplant* 2004. 34:835-8
- 5.2.26 Apperley JF, Bain B. The FIP1L1-PDGFR $\alpha$  syndrome: a case of mistaken identity? *Blood* 2004 104: 2999 – 3000.
- 5.2.27 Burton C, Marin D, Apperley J. Personalized medical treatment strategies for patients with chronic myeloid leukemia. *Expert Rev Anticancer Ther.* 2005 5:343-53.
- 5.2.28 Crawley C, Radich J, Apperley JF. Allogeneic transplantation for CML. *Balliere's Clinical Haematology* 2006 .
- 5.2.29 Apperley JF. Never say never again! *Blood* 2006
- 5.2.30 Apperley JF. Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. *Hematology Am Soc Hematol Educ Program.* 2006 226-32.
- 5.2.31 Chaidos A, Kanfer E, Apperley JF. Risk assessment in haematopoietic stem cell transplantation: disease and disease stage. *Best Pract Res Clini Haematol.* 2007 20: 125-154
- 5.2.32 Smith G, Olavarria E, Richards S, Apperley J, Carella A, Nierderweiser D, Olavarria E, Rowe J, Tallman M, Hehlmann R, et al Autologous stem cell transplantation in chronic myeloid leukaemia: A meta-analysis of six randomized trials. *Cancer Treatment Reviews* 2007 33: 39-47
- 5.2.33 Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. *Lancet Oncol* 2007 8: 1018-1029.
- 5.2.34 Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. *Lancet Oncol* 2007 8: 1116-1128
- 5.2.35 Milojkovic D, Apperley J. State-of-the-art in the treatment of chronic myeloid leukaemia. *Curr Opin Oncol.* 2008 20:112-21.
- 5.2.36 Keating A, Apperley JF, Horowitz M, Horwitz E, LeMaistre F, Warkentin P, Weisdorf D. Blood and marrow transplant organizations. *Hematopoietic Stem Cell Transplantation in Clinical Practice* 513-521
- 5.2.37 Pavlu J, Apperley JF. Allogeneic SCT in chronic phase CML: who should you transplant? *Myeloproliferative Disorders in Practice* 2009 3: 3-5
- 5.2.38 Apperley JF. CML in pregnancy and childhood. *Best Practice & Research Clinical Haematology* 2009 22:455-74.
- 5.2.39 Apperley JF. Issues of imatinib and pregnancy outcome. *Journal of the National Comprehensive Cancer Network* 2009 7:1050-8.
- 5.2.40 Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. *Clin Cancer Res.* 2009 15:7519-7527.
- 5.2.41 Frewer LJ, Coles D, Champion K, Demotes-Mainard J, Goetbuegt N, Ihrig K, Klingmann I, Kubiak C, Lejeune SA, McDonald F, Apperley JF. Has the European Clinical Trials Directive been a success? *BMJ.* 2010; 340: 1862.
- 5.2.42 Apperley JF. Imatinib-should we have more of a good thing? *Nat Rev Clin Oncol* 7:303-304
- 5.2.43 Apperley JF. Regulation of donor participation in research studies: is there another way? *Bone Marrow Transplant* 2010 46:15-6.
- 5.2.44 Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learnt? *Blood.* 2010 117:755-63.

- 5.2.45 Chabannon C, Pamphilon D, Vermynen C, Gratwohl A, Niederwieser D, McGrath E, Lamers C, Lanza F, Slaper-Cortenbach I, Madrigal A, Apperley JF. JACIE celebrates its ten year anniversary with evidence of improved clinical outcome. *Cytotherapy*. 2011 13:765-6. Epub 2011 Feb 7
- 5.2.46 Chabannon C, Pamphilon D, Vermynen C, Gratwohl A, Niederwieser D, McGrath E, Lamers C, Lanza F, Slaper-Cortenbach I, Madrigal A, Apperley JF. Ten years after the first inspection of a candidate European centre, an EBMT registry analysis supports evidence of improved clinical outcome when hematopoietic stem cell transplantation is performed in a JACIE accredited program. *Bone Marrow Transplant*. 2012 47:15-7. Epub 2011 Mar 7.
- 5.2.47 Mohty M, Apperley JF. Long-term physiological side effects after allogeneic bone marrow transplantation. *Hematology Am Soc Hematol Educ Program* 2010:229-236
- 5.2.48 Garland P, Apperley J. Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia. *Future Oncol*. 2011 7:201-18.
- 5.2.49 Pavlů J, Apperley JF. Allogeneic stem cell transplantation for chronic myeloid leukemia. *Current Hematologic Malignancy Reports* 2013 8:43-51.
- 5.2.50 Terpos E, Apperley J, Milojkovic D. Commentary: imatinib and chronic myeloid leukemia: close to the bone. *Leuk Lymphoma*. 2013;54:1581-2
- 5.2.51 Experts in chronic myeloid leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. *Blood* 2013 121:4439-42.
- 5.2.52 Apperley JF. Twist it but don't spin it. *Blood* 2013 122:470-471
- 5.2.53 Milojkovic D, Apperley JF. How I treat leukaemia in pregnancy. *Blood*. 2014 123:974-84. Epub 2013 Nov 22
- 5.2.54 Garnett C, Apperley JF, Pavlů J. Treatment and management of graft-versus-host disease: improving response and survival. *Ther Adv Hematol* 4:366-378 Dec 2013
- 5.2.55 Apperley JF, Gale RP. John Michael Goldman: transplant pioneer 1938-2013. *Biol Blood Marrow Transplant*. 2014 Jan 20
- 5.2.56 Apperley JF, Gale RP. John Michael Goldman: CML pioneer and journal founder 1938-2013. *Bone Marrow Transplant*. 2014 49:161-2
- 5.2.57 Innes AJ, Apperley JF. Chronic Myeloid Leukaemia: transplantation in the tyrosine kinase era. *Hematol Oncol Clin North Am*. 2014 28:1037-1053. Epub 2014 Oct 5.
- 5.2.58 Apperley JF. Chronic Myeloid Leukaemia. *Lancet* 2015 385:1447-59
- 5.2.59 Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukemia. *Ann Hematol*. 2015 94(Supplement 2):167-176. Epub 2015 Mar 27
- 5.2.60 Apperley JF. CML and tyrosine kinase inhibition: the hope becomes reality *Lancet Haem* 2015 April 20 Epub ahead of print
- 5.2.61 Apperley JF. Cancer Drug Fund and CML: an unhappy alliance. *Oncology Central Epub* 2015 Nov 5
- 5.2.62 Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J, Kodera Y. Haploidentical HCT - A Global Overview: comparing Asia, EU and U.S. *Biol Blood Marrow Transplant*. Epub 2015 Nov 6
- 5.2.63 Innes AJ, Milojkovic D, Apperley JF. Allogeneic transplantation for CML in the TKI era: striking the right balance. *Nat Rev Clin Oncol*. 2016 Feb;13(2):79-91

- 5.2.64 Altaf SY, Apperley JF, Olavarria E. Matched unrelated donor transplants-State of the art in the 21st century. *Semin Hematol.* 2016 Oct;53(4):221-229
- 5.2.65 Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ. Chronic myeloid leukaemia: Reminiscences and Dreams. *Haematologica* 2016 101:541-558
- 5.2.66 Oehler V, Apperley JF. Chronic myeloid leukaemia. *American Society of Hematology Self-Assessment Program 7th Edition* 2018
- 5.2.67 Apperley JF, Claudiani S. The argument for using imatinib in CML. *Hematology Am Soc Hematol Educ Program.* 2018 [Epub ahead of print] Nov 2018
- 5.2.68 Abruzzese E, de Fabritiis P, Trawinska MM, Niscola P, Apperley JF, Mauro MJ. Back to the future: TFR and pregnancy in CML. *Eur J Haematol.* 2018 Nov 7 [Epub ahead of print].
- 5.2.69 Gale RP, Apperley J. What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias? *Curr Hematol Malig Rep.* 2019 Dec;14(6):477-479.
- 5.2.70 Gratwohl A, Mohty M, Apperley J. The EBMT: History, Present, and Future. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. *The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet].* 7th edition. Cham (CH): Springer; 2019. Chapter 2.
- 5.3 *Letters*
- 5.3.1 Apperley JF, Marcus RE, Goldman JM, Wardle DG, Gravett PJ, Chanas A. Foscarnet for cytomegalovirus pneumonitis. *Lancet* 1985 i: 1151.
- 5.3.2 Rice SJ, Bishop JA, Apperley JF and Gardner SD. BK virus as a cause of haemorrhagic cystitis after bone marrow transplantation. *Lancet* 1985 ii: 844-845.
- 5.3.3 Atkinson HG, Apperley JF, Dawson K, Goldman JM, Winston R. Successful pregnancy after embryo cryopreservation after BMT for CML. *Lancet* 1994 344: 199.
- 5.3.4 Rule SA, O'Brien SG, Spencer A, Apperley J, Goldman JM. Bone marrow transplantation. Review articles must accurately reflect current practice. *BMJ.* 1995 310:8 74.
- 5.3.5 Ruutu T, Herman J, van Biezen, Niederweiser D, Gratwohl A, Apperley JF. How should corticosteroids be used in the treatment of acute GVHD. *Bone Marrow Transplantation* 1998, 22: 614-615.
- 5.3.5 Cooke F, Bakkus M, Thielemans, K, Apperley JF. Use of quantitative ASO-PCR to predict relapse in myeloma. *British Journal of Haematology* 1999, 105: 317-318.
- 5.3.6 McCann S, Apperley JF, Cohen A, Kolb HJ, Socie G. Late effects of transplantation. *Lancet* 1999 354: 778
- 5.3.7 Gratwohl A, van Biezen A, Hermans J, Apperley JF for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Role of splenic irradiation in patients with chronic myeloid leukaemia undergoing allogeneic bone marrow transplantation. *Biology of Blood and Marrow Transplantation* 2000, 6: 211-212.
- 5.3.8 Cwynarski K, Craddock C, Cobbold M, Apperley JF, Goldman JM. Survival after bone marrow transplantation. *Lancet.* 2002 359: 887-8.
- 5.3.9 Dazzi F, Szydlo RM, Apperley JF, Goldman JM. Prognostic factors for acute graft versus host disease after donor lymphocyte infusions. *Blood* 2002 100:2673-4

- 5.3.10 Goldman JM, Apperley JF, Clark R, Green T, Holyoake T, O'Brien S, Shepherd P. Not so NICE for CML. *Lancet* 2002 359: 2036.
- 5.3.11 Powles R, Apperley J. Major radiation exposure. *N Engl J Med* 2002 347:944-7; discussion 944-7.
- 5.3.12 Marin D, Marktel S, Foot N, Szydlo R, Bua M, Olavarria E, Goldman JM, Apperley JF. G-CSF reverses cytopenia and permits cytogenetic responses in patients with CML treated with imatinib mesylate. *Haematologica* 2003, 88: 260-7.
- 5.3.13 Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G, Dinauer M, Sadat M, Aiuti A, Deola S, Radrizzani M, Hagenbeek A, Apperley JF, Ebeling S, Martens S, Kolb HJ, Weber M, Lotti F, Grande A, Weissinger E, Bueren JA, Lamana M, Falkenburg JHF, Heemskerk MHM, Austin T, Kornblau S, Marini F, Benati C, Magnani Z, Cazzaniga S, Toma S, Gallo-Stampino C, Introna M, Slavin S, Greenberg PD, Bregni M, Mavilio F, Bordignon C. Safety of Retroviral Gene Marking with a Truncated NGF Receptor. *Nature Medicine* 2003, 9:367-9.
- 5.3.14 Goldman JM, Apperley J, Kanfer E, Olavarria E, Marin D. Imatinib or transplant for chronic myeloid leukaemia? *Lancet* 2003, 362: 172
- 5.3.15 Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. *Blood* 2003
- 5.3.16 Kaeda J, Apperley J, Melo J, Cross N, Goldman J. Monitoring CML after nonmyeloablative transplantations: how negative is negative? *Blood* 2003 101:5084
- 5.3.17 Marin D, Rahemtulla A, E, Goldman JM, Apperley JF. Interactive web-based guidelines for chronic myeloid leukaemia: a model for other diseases? *Lancet* 2004 364: 1239
- 5.3.18 Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo J. Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. *Blood* 2005 105: 4803-4804.
- 5.3.19 Elliot V, Marin D, Horncastle D, Elderfield K, Apperley JF, Lampert IA, Naresh K. Percentage of CD34 cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count. *British Journal of Haematology* 2005 130:460-1.
- 5.3.20 Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, Rahemtulla A. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. *Leuk Res.* 2005 30:240-241.
- 5.3.21 Anand M, , Khorashad JS, Marin D, Apperley JM, Goldman JM, Kaeda J. Varying response to escalating the dose of imatinib in CML patients who 'acquire' a BCR-ABL<sup>M244V</sup> mutant allele. *Blood* 2006 108: 2881-2882.
- 5.3.22 de Lavallade H, Khorashad JS, Davis HP, Kaeda JS, Milojkovic D, Goldman JM, Apperley JF, Marin D. Interferon- $\alpha$  or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. *Blood* 2007 110: 2719-2780.
- 5.3.23 De Melo VA, Milojkovic D, Khorashad JS, Marin D, Goldman JM, Apperley JF, Reid AG. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. *Blood* 2007 110: 3086-3087.
- 5.3.24 De Melo V, Vetter M, Mazzullo H, Howard JD, Betts DR, Nacheva EP, Apperley JF, Reid AG. A simple FISH assay for the detection of 3q26 rearrangements in myeloid malignancy. *Leukemia* 2008 22: 434-437
- 5.3.25 Gabriel I, Chaidos A, Sorouri J, Dannie E, Davis J, Goldman JM, Apperley JF, Marin D. Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib. *Leukemia* 2008 22:1618-9.
- 5.3.26 de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, Chaidos A, Olavarria E, Goldman JM, Apperley JF, Marin D. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. *Br J Haematol.* 2008 141:745-7.

- 5.3.27 De Melo VA, Milojkovic D, Marin D, Apperley JF, Nacheva EP, Reid AG. Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements. *Cancer Genet Cytogenet.* 2008 182:111-5.
- 5.3.28 Khorashad JS, De Melo VA, Fiegler H, Gerrard G, Marin D, Apperley JF, Goldman JM, Foroni L, Reid AG. Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis. *Leukemia.* 2008 22:1806-7.
- 5.3.29 Ali S, Sergeant R, O'Brien S, Foroni L, Hedgley C, Gerrard G, Milojkovic D, Stringaris K, Khoder A, Alsuliman A, Gilleece M, Gabriel IH, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. *Blood* 2012,120:697-8. Epub 2012 Apr 24
- 5.3.30 Neelakantan P, Marin D, Laffan M, Goldman JM, Apperley J, Milojkovic D. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. *Haematologica.* 2012 97:1444. Epub 2012 Apr 24.
- 5.3.31 Aduwa E, Szydlo R, Marin D, Foroni L, Reid A, Goldman J, Apperley JF, Milojkovic D. Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy. *Blood.* 2012 120:5087-8
- 5.3.32 Loaiza S, Haynes R, Bray E, Finn SA, Rezvani K, Apperley J, Davis J. Donor lymphocyte collections using the spectra Optia MNC version 5. *Transfus Apher Sci.* 2013 48:171. Epub 2013 Mar 13.
- 5.3.33 Dharmagunawardena R, Pearce RM, Thomas G, Kirkland K, Perry J, Apperley JF, Medd P, Wilson KM, Orchard K, Jackson G, Snowden JA, Cook G, Brown JS; on behalf of the British Society of Blood and Marrow Transplantation, Clinical Trials Committee. A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function *Bone Marrow Transplant.* 2014 49:1442-3 [Epub ahead of print Jul 21]
- 5.3.34 Gale RP, Apperley JF. Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same. *Bone Marrow Transplant.* 2015 Epub ahead of print Sep 14.
- 5.3.35 Patel A, Szydlo RM, Auner HW, Kanfer EJ, MacDonald DH, Milojkovic D, Altaf S, Innes A, Gabriel I, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlů J. C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality. *Br J Haematol.* 2018 180: 889-892
- 5.3.36 Innes AJ, Mullish BH, Fernando F, Adams G, Marchesi JR, Apperley JF, Pavlu J. Faecal microbiota transplant prior to hematopoietic cell transplantation; A novel biological approach to minimizing multi-drug resistance organisms-related mortality. *European Journal of Hematology* 2017 52:1452-1454
- 5.3.37 Claudiani S, Apperley JF, Gale RP, Clark R, Szydlo R, Deplano S, Palanicawandar R, Khorashad J, Foroni L, Milojkovic D. E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy. *Hematologica* 2017 102:e297-e299.
- 5.3.38 Hanley B, Nesr G, Yebra-Fernandez E, Brown L, Killeen N, Apperley JF, Naresh K. T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving Nilotinib: first documented report. *J Clin Path* 2019. [Epub ahead of print]
- 5.3.39 Nesr G, Claudiani S, Khorashad J, Apperley J, Milojkovic D. The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients. *Leuk Lymphoma.* 2019 60:3333-3334.
- 5.3.40 Nesr G, Laffan M, Claudiani S, Innes A, Apperley J, Milojkovic D. Platelet function in patients with chronic myeloid leukemia treated with asciminib. *Leuk Lymphoma.* 2020 61:3021-3023
- 5.3.41 Innes AJ, Cook LB, Marks S, Bataillard E, Crossette-Thambiah C, Sivasubramaniam G, Apperley J, Milojkovic D. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection *Br J Haematol.* 2020 190:e198-e200.

5.3.42 Gallipolli P, Clark RE, Byrne J, Milojkovic Dm Apperley JF, Foronii L, Goldman JM, O'Brien S. The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML) British Journal of Haematology 2021 [Epub ahead of print].

5.3.43 Claudiani S, Apperley JF, Parker E, Marchesin F, Katsanovskaja K, Palanicawandar R, Innes AJ, Tedder RS, McClure M, Milojkovic D. Durable humoral responses to anti-SARS-CoV-2 vaccines in chronic myeloid leukemia patients on TKI. Brit J Haem 2021 [Epub ahead of print]